var title_f32_5_32848="Minoxidil: Drug information";
var content_f32_5_32848=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Minoxidil: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12618228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/38/11877?source=see_link\">",
"       Minoxidil (systemic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/47/27379?source=see_link\">",
"       Minoxidil (topical): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9655 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-F0C764AA00-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_5_32848=[""].join("\n");
var outline_f32_5_32848=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/38/11877?source=related_link\">",
"      Minoxidil (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/47/27379?source=related_link\">",
"      Minoxidil (topical): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_5_32849="AML FAB M6";
var content_f32_5_32849=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F52638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F52638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythroleukemia (M6)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 423px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow smear from a patient with erythroleukemia (FAB classification M6). (Wright-Giemsa stain.) A megaloblastoid erythroblast (blue arrow) is shown along with three myeloblasts (black arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Brunning RD, McKenna RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_5_32849=[""].join("\n");
var outline_f32_5_32849=null;
var title_f32_5_32850="Methylfolate: Drug information";
var content_f32_5_32850=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methylfolate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/29/24019?source=see_link\">",
"    see \"Methylfolate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6058906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Deplin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6122001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Dietary Supplement",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6122075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Medicinal food:",
"     </b>",
"     Oral: 7.5-15 mg daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F6122076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6122078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral: L-methylfolate 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Deplin&reg;: L-methylfolate 15 mg [gluten free, sugar free; contains tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: L-methylfolate 7.5 mg, L-methylfolate 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Deplin&reg;: L-methylfolate 7.5 mg [gluten free, sugar free]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6121999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F16317929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6122002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Medicinal food for the nutritional requirements of patients with suboptimal L-methylfolate and have major depressive disorder or who have or are at risk for hyperhomocysteinemia and have schizophrenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6122063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6122064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Anemia: Monotherapy: Not appropriate for monotherapy with pernicious or other megaloblastic anemias when anemia is present with vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pernicious anemia: Doses &gt;0.1 mg/day may obscure pernicious anemia with continuing irreversible nerve damage progression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Medicinal food: Product is a medicinal food for use only under the supervision of a healthcare provider.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6122067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Methylfolate may decrease the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholestyramine Resin: May decrease the serum concentration of Methylfolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colestipol: May decrease the serum concentration of Methylfolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Methylfolate may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Methylfolate may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: Methylfolate may decrease the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Methylfolate may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: Methylfolate may decrease the serum concentration of Primidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pyrimethamine: Methylfolate may diminish the therapeutic effect of Pyrimethamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltitrexed: Methylfolate may diminish the therapeutic effect of Raltitrexed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SulfaSALAzine: May decrease the serum concentration of Methylfolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Methylfolate may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13376202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal and human reproduction studies have not been located. Methylfolate is the active form of folic acid, which is required during pregnancy; folic acid deficiency may result in fetal harm.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F6179934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Deplin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg (30): $98.73",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (L-Methylfolate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg (90): $259.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (90): $259.81",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6122071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Methylfolate, or L-methylfolate, is the active form of folate in the body, which can be transported into peripheral tissues and across the blood-brain barrier. Folate is necessary for formation of numerous coenzymes in many metabolic systems, particularly for purine, pyrimidine, and nucleoprotein synthesis, and maintenance in erythropoiesis; stimulates WBC and platelet production in folate deficiency anemia.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10342 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-27.109.116.13-B2EFA6BE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_5_32850=[""].join("\n");
var outline_f32_5_32850=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6058906\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6122001\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6122075\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6122076\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6122078\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6121999\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16317929\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6122002\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6122063\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6122064\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299701\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6122067\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13376202\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6179934\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6122071\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10342\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10342|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/29/24019?source=related_link\">",
"      Methylfolate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_5_32851="Treatment of male infertility";
var content_f32_5_32851=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Treatment of male infertility (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?32/5/32851/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/5/32851/contributors\" id=\"au4065\">",
"       Christina Wang, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/5/32851/contributors\" id=\"au6711\">",
"       Ronald S Swerdloff, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?32/5/32851/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/5/32851/contributors\" id=\"se5918\">",
"       Peter J Snyder, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?32/5/32851/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/5/32851/contributors\" id=\"de5123\">",
"       Kathryn A Martin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?32/5/32851?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      MALE INFERTILITY OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Infertility is defined as a couple's inability to become pregnant after one year of unprotected intercourse. In any given year, about 15 percent of couples in North America and Europe who are trying to conceive are infertile.",
"    </p>",
"    <p>",
"     The fertility of a couple depends upon several factors in both the male and female partner. Among all cases of infertility in developed countries, about 8 percent can be traced to male factors, 37 percent can be traced to female factors, 35 percent can be traced to factors in both the male and female partners, and 5 percent cannot be traced to obvious factors in either partner [",
"     <a class=\"abstract\" href=\"mobipreview.htm?32/5/32851/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     When infertility occurs, the male and female partners are evaluated to determine the cause and best treatment options. In the past, men with infertility had few options because there was limited information about causes and even less information about successful treatment. However, new tests have made it possible to determine the causes of male infertility and treatments, and assisted reproductive techniques (ART) offer hope to many couples.",
"    </p>",
"    <p>",
"     Separate articles discuss the treatment of female infertility (see",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34883?source=see_link\">",
"      \"Patient information: Ovulation induction with clomiphene (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/14/10468?source=see_link\">",
"      \"Patient information: Infertility treatment with gonadotropins (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/62/40932?source=see_link\">",
"      \"Patient information: In vitro fertilization (IVF) (Beyond the Basics)\"",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      MALE INFERTILITY CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     Fertility in men requires normal functioning of the hypothalamus and pituitary gland (hormone-producing glands in the brain), and the testes (",
"     <a class=\"graphic graphic_figure graphicRef65294 \" href=\"mobipreview.htm?31/46/32486\">",
"      figure 1",
"     </a>",
"     ). Therefore, a variety of conditions can lead to infertility.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       30 to 40 percent of cases are due to problems in the testes (of which about 15 to 25 percent are due to genetic causes)",
"      </li>",
"      <li>",
"       10 to 20 percent are due to a blockage in the pathway that sperm use to exit the testes during ejaculation; this can be caused by prior infection (",
"       <a class=\"graphic graphic_figure graphicRef68075 \" href=\"mobipreview.htm?21/43/22194\">",
"        figure 2",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       1 to 2 percent of cases are due to conditions of the pituitary gland or hypothalamus",
"      </li>",
"      <li>",
"       40 to 50 percent of cases have no identifiable cause, even after an evaluation",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      MALE INFERTILITY EVALUATION",
"     </span>",
"    </p>",
"    <p>",
"     A separate article discusses the evaluation of infertility in men. The most important test for infertile men is a semen analysis (sperm evaluation). A normal result tells you that the male partner most likely does not have an infertility problem. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/42/22180?source=see_link\">",
"      \"Patient information: Evaluation of the infertile couple (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      MALE INFERTILITY TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The treatment of male infertility depends upon the underlying cause. Several months to years of treatment are usually necessary to achieve fertility. The treatment often involves both male and female partners.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H61150384\">",
"     <span class=\"h2\">",
"      Blockage of the reproductive tract",
"     </span>",
"     &nbsp;&mdash;&nbsp;Men who have a blockage in the ducts conveying the sperm from the testis until ejaculation (so that sperm cannot get out) can undergo surgery to correct the blockage. If it is not successful, another option is assisted reproductive technologies using sperm retrieved from the testes. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3610?source=see_link&amp;anchor=H21#H21\">",
"      \"Treatment of male infertility\", section on 'Retrieval of sperm from the testis'",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Vasectomy (male sterilization) is a different type of blockage. Vasectomies can be reversed in up to 85 percent of cases; over 50 percent of couples can achieve pregnancy following vasectomy reversal. However, the more time that has passed since the vasectomy, the less likely vasectomy reversal is to restore fertility.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Treatment of hypothalamic or pituitary deficiency",
"     </span>",
"     &nbsp;&mdash;&nbsp;In a small percentage of cases (1 to 2 percent), male infertility is due to problems in the hypothalamus and pituitary gland (parts of the brain that regulate hormone production). In this case, treatment with human chorionic gonadotropin (hCG), recombinant human follicle stimulating hormone (rhFSH), also called gonadotropin treatment, is often given.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1234368\">",
"     <span class=\"h3\">",
"      Gonadotropin treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Gonadotropin treatment is started with injections of hCG three times per week (or sometimes every other day) for up to six months. Blood tests are used to monitor blood testosterone levels and to adjust the dose if necessary. If sperm cells do not appear in semen after six months of treatment, recombinant human follicle stimulating hormone (rhFSH) is added; this is also given by injection. The success rate for this therapy is high as most men will eventually develop sperm in the ejaculate. In many cases, a total of one to two years of treatment is needed to achieve normal fertility. The cost of these treatments can be significant, especially if health insurance does not cover the costs of infertility treatments.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Varicocele",
"     </span>",
"     &nbsp;&mdash;&nbsp;A varicocele is a dilation of a vein (like a varicose vein) in the scrotum. Many men with varicocele have a low sperm count or abnormal sperm morphology (shape). The reason a varicocele affects the sperm may be related to a higher than normal temperature in the testicles, poor oxygen supply, and poor blood flow in the testes.",
"    </p>",
"    <p>",
"     Varicocele can be treated surgically by cutting the veins connected to the varicocele. However, surgery does not always improve fertility and is not recommended for most men unless there is a large varicocele. A varicocele that has been present for a long time can cause irreversible damage that cannot be surgically treated.",
"    </p>",
"    <p>",
"     An alternative to varicocele repair is assisted reproductive techniques (ART), such as intracytoplasmic sperm injection (ICSI). With ICSI, only a small number of sperm are needed (see",
"     <a class=\"local\" href=\"#H13\">",
"      'Intracytoplasmic sperm injection (ICSI)'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H61150472\">",
"     <span class=\"h2\">",
"      Other",
"     </span>",
"     &nbsp;&mdash;&nbsp;Treatment is not currently available for most types of male infertility. For example, there is no known treatment when the sperm-producing structures of the testes have been severely damaged or are abnormal. This happens in men with certain chromosomal abnormalities such as Klinefelter syndrome and small deletions in the Y (male specific) chromosome (see",
"     <a class=\"local\" href=\"#H15\">",
"      'When infertility cannot be treated'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      ASSISTED REPRODUCTIVE TECHNIQUES",
"     </span>",
"    </p>",
"    <p>",
"     If the male partner's semen contains few sperm, no sperm, abnormal sperm, or sperm with poor motility, assisted reproductive techniques can often help. These techniques offer hope to some infertile couples who could not achieve pregnancy without them.",
"    </p>",
"    <p>",
"     However, the techniques are expensive, require a considerable commitment of time and energy, may pose certain health risks, and may have disappointingly low success rates. Couples should discuss the pros, cons, and success rates of these techniques with an infertility specialist.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      In vitro fertilization (IVF)",
"     </span>",
"     &nbsp;&mdash;&nbsp;IVF is a commonly used technique for a variety of infertility problems, including female tubal blockages and unexplained infertility. IVF is usually recommended with ICSI for men with infertility. (See",
"     <a class=\"local\" href=\"#H13\">",
"      'Intracytoplasmic sperm injection (ICSI)'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     IVF success rates depend upon a number of variables, including the age and health of the woman, health of the male sperm and female egg, and to some extent, the experience of the infertility center. Approximately 28 percent of IVF cycles result in pregnancy, and 82 percent of those pregnancies result in the birth of one or more children. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/62/40932?source=see_link\">",
"      \"Patient information: In vitro fertilization (IVF) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Intracytoplasmic sperm injection (ICSI)",
"     </span>",
"     &nbsp;&mdash;&nbsp;ICSI is a procedure that is performed in conjunction with IVF. With ICSI, a single sperm from the male partner is injected directly into a woman's egg (oocyte) in the laboratory. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/11/15546?source=see_link\">",
"      \"Intracytoplasmic sperm injection\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     This technique can be useful in many cases of low sperm count. The pregnancy rate with ICSI is approximately 20 to 40 percent per cycle, although the technique is expensive.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H560880\">",
"     <span class=\"h2\">",
"      Testicular extraction of sperm (TESE)",
"     </span>",
"     &nbsp;&mdash;&nbsp;If a man's semen completely lacks sperm in the ejaculate (azoospermia), sperm can sometimes be directly removed from the testes. This is done in a minor surgery or by using a needle to aspirate semen under local anesthesia. If sperm can be found and extracted from the testis, the sperm will be used for ICSI and the fertilization rate of the oocyte is not very different from IVF. Thus, men with no sperm in the ejaculate can have a potential of fathering a child using these techniques.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Risks of ART",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most patients who undergo ART have no major complications. There are few to no risks for men, depending upon the procedure used to obtain sperm. Men who must undergo a procedure to retrieve sperm have a small risk of bleeding, damage to the testes, and infection.",
"    </p>",
"    <p>",
"     Risks of ART for women include infection and damage to blood vessels, reproductive, or surrounding organs. The ovarian hyperstimulation syndrome (OHSS) is a potentially life-threatening complication that can occur during the process of IVF. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/62/40932?source=see_link\">",
"      \"Patient information: In vitro fertilization (IVF) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     There is some evidence that children of couples who become pregnant after IVF or ICSI have a slightly higher rate of chromosomal or congenital (birth) abnormalities and may have a higher rate of lower birth weight. This potential risk should be discussed with an infertility specialist. For now, couples can be reassured that these conditions are rare and the absolute risk of having a child with a congenital anomaly is low (the population baseline risk is 2 to 4 percent, which is potentially increased by about one-third with ART).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      WHEN INFERTILITY CANNOT BE TREATED",
"     </span>",
"    </p>",
"    <p>",
"     Some treatments for male infertility fail, and some cases of male infertility simply cannot be treated at this time. If this is this case, an infertility specialist can advise the couple of available alternatives. Each couple's choice is a very personal one.",
"    </p>",
"    <p>",
"     Men with irreversible infertility and testosterone deficiency may benefit from testosterone treatment. Although this treatment may not address a couple's goal of having a child, it can improve the male partner's sexual function and mood and help increase and maintain bone and muscle mass. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/33/29205?source=see_link\">",
"      \"Patient information: Sexual problems in men (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Artificial insemination with donor sperm",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some couples affected by irreversible male infertility consider artificial insemination of the female partner with donor sperm. Donor sperm may be obtained from a sperm bank, which screens men for infections, certain genetic problems, and provides a complete personal and family history. Most sperm banks keep the identity of their donors confidential; some banks give donors the option to be contacted by the children conceived with their sperm.",
"    </p>",
"    <p>",
"     The decision to use donor sperm, whether from a known or unknown donor, can be complicated and difficult for a couple. Counseling may be helpful to help both partners discuss their feelings and the potential implications of using donor sperm. The American Society for Reproductive Medicine recommends that parents discuss their child's genetic origins with the child. The optimal age for this discussion is not known, although most experts recommend that the child be told before he or she is an adolescent (before approximately age 13) [",
"     <a class=\"abstract\" href=\"mobipreview.htm?32/5/32851/abstract/2\">",
"      2",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     The use of donor sperm has a high success rate; pregnancy rates are about 50 percent after six cycles of insemination. Insemination may be done without the use of infertility medications or monitoring in women who have no infertility. Women who have difficulty conceiving may require intrauterine insemination or in vitro fertilization. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/14/10468?source=see_link\">",
"      \"Patient information: Infertility treatment with gonadotropins (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Adoption",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some couples affected by irreversible male infertility consider adopting a child. A healthcare provider or social worker can suggest resources for couples who decide to pursue this option. Approximately 2 to 4 percent of American families include an adopted child.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Childlessness",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some couples affected by irreversible male infertility decide to remain childless. Couples who decide to remain childless often face questions from friends or family regarding their decision. These questions can be hurtful for couples who have struggled with infertility. Couples often benefit from counseling after they decide to stop infertility treatments; communicating openly is important to maintain a healthy relationship.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784889639\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H181962010\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/16/11523?source=see_link\">",
"      Patient information: Infertility in women (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/25/6547?source=see_link\">",
"      Patient information: Infertility in couples (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/51/31538?source=see_link\">",
"      Patient information: Testicular cancer (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H181962056\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34883?source=see_link\">",
"      Patient information: Ovulation induction with clomiphene (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/14/10468?source=see_link\">",
"      Patient information: Infertility treatment with gonadotropins (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/62/40932?source=see_link\">",
"      Patient information: In vitro fertilization (IVF) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/42/22180?source=see_link\">",
"      Patient information: Evaluation of the infertile couple (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/33/29205?source=see_link\">",
"      Patient information: Sexual problems in men (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/54/11114?source=see_link\">",
"      Causes of male infertility",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30536?source=see_link\">",
"      Causes of primary hypogonadism in males",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/18/8488?source=see_link\">",
"      Causes of secondary hypogonadism in males",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12824?source=see_link\">",
"      Clinical features and diagnosis of male hypogonadism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/24/13706?source=see_link\">",
"      Effects of cytotoxic agents on gonadal function in adult men",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40921?source=see_link\">",
"      Evaluation of female infertility",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33481?source=see_link\">",
"      Evaluation of male infertility",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/61/23510?source=see_link\">",
"      Induction of fertility in men with secondary hypogonadism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/11/15546?source=see_link\">",
"      Intracytoplasmic sperm injection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3610?source=see_link\">",
"      Treatment of male infertility",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25496?source=see_link\">",
"      Unexplained infertility",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hormone.org/public/other.cfm\">",
"      www.hormone.org/public/other.cfm",
"     </a>",
"     , also available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society for Reproductive Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.asrm.com/\">",
"      www.asrm.com/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Resolve: The National Infertility Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.resolve.org/\">",
"      www.resolve.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The International Council on Infertility Information Dissemination",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.inciid.com/\">",
"      www.inciid.com",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Patient Support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Infertility Conditions Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://infertility.about.com/forum\">",
"      file://infertility.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?32/5/32851/abstract/3-6\">",
"      3-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 5, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?32/5/32851?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     WHO Technical Report Series. Recent Advances in Medically Assisted Conception Number 820, 1992, pp 1-111.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32851/abstract/2\">",
"      Ethics Committee of the American Society for Reproductive Medicine. Informing offspring of their conception by gamete donation. Fertil Steril 2004; 82 Suppl 1:S212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32851/abstract/3\">",
"      De Kretser DM, Baker HW. Infertility in men: recent advances and continuing controversies. J Clin Endocrinol Metab 1999; 84:3443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32851/abstract/4\">",
"      Meng MV, Greene KL, Turek PJ. Surgery or assisted reproduction? A decision analysis of treatment costs in male infertility. J Urol 2005; 174:1926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32851/abstract/5\">",
"      Foresta C, Bettella A, Garolla A, et al. Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study. Fertil Steril 2005; 84:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32851/abstract/6\">",
"      Munkelwitz R, Gilbert BR. Are boxer shorts really better? A critical analysis of the role of underwear type in male subfertility. J Urol 1998; 160:1329.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f32_5_32851=[""].join("\n");
var outline_f32_5_32851=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           MALE INFERTILITY OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           MALE INFERTILITY CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           MALE INFERTILITY EVALUATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           MALE INFERTILITY TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           ASSISTED REPRODUCTIVE TECHNIQUES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           WHEN INFERTILITY CANNOT BE TREATED",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/46/32486\" title=\"figure 1\">",
"           HPG axis PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/43/22194\" title=\"figure 2\">",
"           Male anatomy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f32_5_32852="Male palpable lump";
var content_f32_5_32852=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 482px\">",
"   <div class=\"ttl\">",
"    Male with palpable lump",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 462px; height: 388px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CC and MLO views in a male with a palpable lump behind the nipple. The mammograms show an irregular, dense, spiculated mass. The mammographic appearance of breast cancer in a male is similar to that in a female.",
"    <div class=\"footnotes\">",
"     CC: craniocaudal; MLO: mediolateral oblique.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_5_32852=[""].join("\n");
var outline_f32_5_32852=null;
var title_f32_5_32853="Fosamprenavir: Patient drug information";
var content_f32_5_32853=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fosamprenavir: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/11/44217?source=see_link\">",
"     see \"Fosamprenavir: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/28/36297?source=see_link\">",
"     see \"Fosamprenavir: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F174255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lexiva&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Telzir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat HIV infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702163",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fosamprenavir, amprenavir, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have hemophilia, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), this drug may sometimes raise blood sugar. Talk with your doctor about how to fine tune this.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697269",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high cholesterol, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697729",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy in HIV disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696918",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use a hormone-related kind of birth control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696711",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not breast-feed if you have HIV disease unless your doctor tells you to.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698138",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood sugar may cause diabetes while on this drug. This most often goes back to normal when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698150",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High triglyceride level.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697889",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain or heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697937",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in body fat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698995",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pain when passing urine or blood in urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699137",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pain in side.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More trips to the bathroom, more thirst, or weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698605",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain, belly pain, or blood in the urine. May be signs of a kidney stone.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695142",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If taking this drug with ritonavir, take with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid taking this drug with high-fat meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705561",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Suspension:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696408",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you throw up within 30 minutes of taking this drug, take 1 more dose.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store tablets at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699442",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) at room temperature or in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11492 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-E8E148C781-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_5_32853=[""].join("\n");
var outline_f32_5_32853=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174255\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855138\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023925\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023927\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023926\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023931\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023932\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023934\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023929\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023930\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023935\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023936\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?43/11/44217?source=related_link\">",
"      Fosamprenavir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/28/36297?source=related_link\">",
"      Fosamprenavir: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_5_32854="RPL CT and MRI findings A";
var content_f32_5_32854=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F79338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F79338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT and MRI images in reversible posterior leukoencephalopathy syndrome (RPLS) (A)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 506px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT image (A) shows hypodensity in the posterior white matter. MRI was obtained one day following CT, and T2-weighted image (B) shows hyperintensity in the white matter of the occipital lobes. FLAIR image (C) obtained more rostrally shows multifocal areas of hyperintensity both posteriorly and anteriorly; note that on the FLAIR image, the hyperintensity involves the gray as well as the white matter. Post-contrast T1-weighted coronal image (D) shows gyriform and nodular enhancement in the occipital lobes consistent with breakdown of the blood brain barrier.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D Schwartz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_5_32854=[""].join("\n");
var outline_f32_5_32854=null;
var title_f32_5_32855="Stereotactic cranial radiosurgery";
var content_f32_5_32855=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Stereotactic cranial radiosurgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/5/32855/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/5/32855/contributors\">",
"     Clark C Chen, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/5/32855/contributors\">",
"     Paul H Chapman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/5/32855/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/5/32855/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/5/32855/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/5/32855/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/5/32855/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/5/32855/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential utility of ionizing radiation to treat cancer was recognized shortly after the discovery of x-rays, which can cause extensive damage to DNA.",
"   </p>",
"   <p>",
"    Prior to the development of stereotactic techniques, radiation was delivered to the cancer and a significant volume of surrounding normal tissue. Therapeutic efficacy was based upon the increased DNA-repair capacity of normal cells compared to tumor cells following radiation exposure. The total dose of radiation was delivered in small fractions over a period of weeks to allow normal tissue to preferentially recover or heal itself between doses compared with the tumor so that the cumulative damage to tumor cells was much greater. This fractionated approach is known as radiation therapy (RT) (",
"    <a class=\"graphic graphic_figure graphicRef80485 \" href=\"mobipreview.htm?27/57/28560\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Major advances in stereotactic localization, noninvasive neuroimaging, and radiation physics made it possible to selectively irradiate a sharply defined target, largely sparing the surrounding normal tissue. This approach, called stereotactic radiosurgery (SRS), is achieved by focusing multiple radiation beams on the tumor tissue from different directions (",
"    <a class=\"graphic graphic_figure graphicRef80485 \" href=\"mobipreview.htm?27/57/28560\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The biologic differences between fractionated RT and SRS and the technology of administering SRS are reviewed here. The applications of SRS for various tumors (both malignant and nonmalignant) are discussed under separate headings. Similarly the potential complications of cranial SRS and the application of SRS to extracranial sites are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/32/2566?source=see_link\">",
"     \"Complications of cranial stereotactic radiosurgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/21/43350?source=see_link\">",
"     \"Stereotactic body radiation therapy: Rationale and clinical experience\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Fractionated (conventional) RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractionated or conventional RT refers to the repeated administration of small doses of radiation to a relatively large target, as in whole brain RT or focal (involved-field) RT. Fractionation of the total dose minimizes damage to normal tissues by allowing time for repair of damage to DNA and maximizes the killing of tumor cells. Conventional dose fractionation schemes for intracranial lesions typically consist of 1.8 to 2.0 Gy in daily sessions with cumulative doses of 30 to 60 Gy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32855/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Stereotactic radiosurgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;SRS refers to the delivery of a single or very limited number of relatively large doses of radiation administered to a small, precisely-defined target. This is achieved by using multiple, non-parallel radiation beams that converge on the target lesion (",
"    <a class=\"graphic graphic_figure graphicRef80485 \" href=\"mobipreview.htm?27/57/28560\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32855/abstract/2\">",
"     2",
"    </a>",
"    ]. The full therapeutic dose is limited to the area where all of the beams overlap, while non-target areas receive much smaller doses from one or a limited number of the radiation beams. SRS thus requires accurate localization of the lesion and patient positioning during treatment.",
"   </p>",
"   <p>",
"    The SRS dose is defined by the amount of radiation given at the margin of the targeted lesion; this is referred to as the prescription dose. Typically, the marginal dose delivered in a single session ranges from 11 Gy (for the treatment of benign lesions) to as much as 70 Gy (for thalamotomy, in the treatment of movement disorders) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32855/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The amount of radiation absorbed by tissues in adjacent nontarget areas decreases rapidly with increasing distance from the target.",
"   </p>",
"   <p>",
"    In some instances, the SRS dose is divided into a very limited number of fractions, up to a maximum of five. Although this was referred to as hypofractionated radiotherapy at one time, this technique is now generally included in the definition of SRS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32855/abstract/5\">",
"     5",
"    </a>",
"    ]. The term stereotactic radiotherapy is now reserved for highly fractionated schedules that rely upon the differential sensitivity of tumor and normal tissue to radiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RADIOBIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Fractionated RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small, daily fractions of radiation cumulatively damage rapidly proliferating tumor cells more than normal tissues. The theoretical framework for dose fractionation was established in the 1960s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32855/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. The basic principles are often referred to as the four R's:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Repair &mdash; Small doses of radiation cause sublethal levels of DNA damage, and normal tissues repair this damage more effectively than tumor cells do.",
"     </li>",
"     <li>",
"      Reoxygenation &mdash; Tumors often contain areas of hypoxia that cause resistance to radiation-induced cell killing. Dose fractionation can improve circulation and oxygenation within the tumor, thereby maximizing the effects of radiation.",
"     </li>",
"     <li>",
"      Redistribution and repopulation &mdash; Tumor cells proceed through the cell cycle differently from normal cells following irradiation. Most normal cells linger in the S phase of the cell cycle after exposure to radiation; during the S phase, cells are highly resistant to further damage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/5/32855/abstract/7\">",
"       7",
"      </a>",
"      ]. In contrast, tumor cells continue to proceed through the cell cycle (redistribute) and proliferate (repopulate) despite radiation exposure. Thus, the tumor cells move out of the radioresistant phase of the cell cycle and are more radiosensitive than normal cells during subsequent treatments.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Stereotactic radiosurgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;SRS delivers a single or very limited number of fractions of high dose of radiation to a well-defined tumor volume, rather than repeated small fractions to both cancer and normal cells. Protection of normal tissue is achieved through a progressive, steep decline in the dose outside the treatment target.",
"   </p>",
"   <p>",
"    The focusing of radiation on the target results from the convergence of multiple, non-parallel beams of radiation (",
"    <a class=\"graphic graphic_figure graphicRef80485 \" href=\"mobipreview.htm?27/57/28560\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32855/abstract/2\">",
"     2",
"    </a>",
"    ]. The dose of radiation received by the normal tissue in each path of the beam is small except where the beams converge. As an analogy, if everyone in an unlit, crowded stadium focused a flashlight on a single point, the point of convergence would be bright while the rest of the stadium remained relatively dark.",
"   </p>",
"   <p>",
"    The prerequisites for SRS include precise delineation of the target using neuroimaging, an understanding of the neuroanatomy of the brain surrounding the lesion, and the technology required to deliver radiation reliably and precisely to the lesion. The planning and administration of SRS thus requires close collaboration between radiation oncologists, neurosurgeons, and medical physicists.",
"   </p>",
"   <p>",
"    The cellular processes triggered by single or a few high-dose radiation fractions are poorly understood but appear to differ from those of much smaller fractionated doses of radiation. Impairment of DNA repair, redistribution, repopulation, and reoxygenation are less important with SRS than with fractionated RT. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Fractionated RT'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    This is illustrated by the clinical results of treating brain metastases using either of the two methods. Whereas whole brain RT is only marginally effective for radioresistant tumors such as melanoma and renal cell carcinoma, SRS is as effective for these tumors as it is for radiosensitive tumors such as breast and lung. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44601?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of brain metastases in favorable prognosis patients\", section on 'Stereotactic radiosurgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effectiveness of SRS cannot be explained entirely by the large dose of radiation simply killing all the tumor cells. Several observations support a more complex mechanism of action, possibly involving the host immune response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32855/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The dose used to control cerebral metastasis (14 to 20 Gy) does not sterilize tumor cell lines in vitro. Following such irradiation in vitro, 0.01 to 1 percent of tumor cells survive, and the remaining tumor cells repopulate the tissue culture plate within days to weeks.",
"     </li>",
"     <li>",
"      Biopsies after SRS typically reveal tumor cells, although active tumor growth is rarely observed.",
"     </li>",
"     <li>",
"      Complete tissue destruction in vivo requires radiation doses significantly higher than those required for local tumor control. As an example, more than 70 Gy of radiation is required to achieve complete cell killing in thalamotomy for the treatment of movement disorders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/5/32855/abstract/4\">",
"       4",
"      </a>",
"      ], whereas only 14 to 20 Gy of radiation is required to achieve local control in the treatment of cerebral metastasis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/5/32855/abstract/3,9\">",
"       3,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with cerebral metastases that are surgically removed because of progressive growth more than five months after SRS, pathology shows a moderate to intense inflammatory cell response [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/5/32855/abstract/10\">",
"       10",
"      </a>",
"      ]. In contrast, when progression occurs less than five months after SRS, such a response is absent or limited.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Dose homogeneity",
"    </span>",
"    &nbsp;&mdash;&nbsp;With fractionated RT, delivery of a homogeneous dose of radiation within the target volume is highly desirable. Uneven distribution of radiation doses may increase killing of tumor cells, but also may increase destruction of normal tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32855/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Since the goal of SRS is to treat well-circumscribed lesions with little or no normal parenchyma in the target, dose homogeneity is less critical.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SRS VERSUS CONVENTIONAL RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple factors influence the decision of whether to use SRS or conventional RT. These include the volume of the target lesion, its proximity to cranial nerves such as the optic nerves, and the specific area of the brain to be irradiated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Tumor volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the size of the target lesion for SRS increases, incidental irradiation of surrounding normal tissue also increases. This may be important since a much higher dose of irradiation per fraction is administered with SRS compared to conventional RT.",
"   </p>",
"   <p>",
"    A dose escalation study conducted by the Radiation Therapy Oncology Group (RTOG) defined the maximally tolerated SRS dose in the treatment of cerebral metastasis as a function of tumor size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32855/abstract/14\">",
"     14",
"    </a>",
"    ]. The recommended marginal doses of SRS were 24, 18, and 15 Gy for lesions &le;2 cm, 2 to 3 cm, and 3 to 4 cm in the largest diameter. SRS was not recommended for lesions &gt;4 cm because adequate control could not be achieved without an unacceptable level of radiation toxicity to surrounding normal tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Proximity to cranial nerves",
"    </span>",
"    &nbsp;&mdash;&nbsp;The close proximity of a target to cranial nerves can cause radiation neurotoxicity, despite the steep decrease in dose outside the intended target. Factors that increase the risk of damage to cranial nerves include previous surgery or radiation, a large volume irradiated, and a high total radiation dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32855/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Fractionated RT should be considered when SRS may jeopardize cranial nerve function.",
"   </p>",
"   <p>",
"    Cranial nerves II and VIII are more sensitive to radiation injury than the other cranial nerves. SRS is generally avoided if the maximal dose delivered to the optic nerve exceeds 10 Gy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32855/abstract/3,17-19\">",
"     3,17-19",
"    </a>",
"    ]. Assessment of damage to cranial nerve VIII with SRS is difficult since it is often radiated during treatment of vestibular schwannoma (acoustic neuroma). In this situation, damage can be due to the tumor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40232?source=see_link&amp;anchor=H14#H14\">",
"     \"Vestibular schwannoma (acoustic neuroma)\", section on 'Stereotactic radiosurgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The proximity of target lesions to cranial nerves other than II and VIII is not a major factor in deciding between SRS and RT, since other cranial nerves are more resistant to damage:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neuropathies of cranial nerves III, IV, and VI have not been reported for doses &lt;15 Gy delivered to the cavernous sinus, while doses of 15 to 40 Gy are associated with injury in 10 to 15 percent of cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/5/32855/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cranial nerve VII routinely receives doses of 11 to 15 Gy with SRS for vestibular schwannoma, but facial neuropathy is rare (less than 1 percent in a series of 829 patients followed for 10 years) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/5/32855/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      SRS for jugular foramen schwannomas or skull base meningiomas has been associated with less than a 2 percent incidence of neuropathy involving cranial nerves IX, X, or XI using doses of 8 to 12 Gy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/5/32855/abstract/22-25\">",
"       22-25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Location of the lesion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of developing permanent damage following SRS varies dramatically with the location of the lesion in the brain. This was illustrated by a series of 422 patients treated with SRS for arteriovenous malformations, 85 of whom (20 percent) developed significant toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32855/abstract/26\">",
"     26",
"    </a>",
"    ]. In a multivariate analysis, the maximum risk of neurologic complications was seen when the lesions were located in the deep gray matter (thalamus, basal ganglia) or brainstem (pons, midbrain), while complications were least likely with lesions in the frontal and temporal lobes. For this reason, fractionated RT is often preferred to SRS for the treatment of lesions in the deep gray matter or the brainstem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Stereotactic guidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precision in target localization is a prerequisite for successful SRS.",
"   </p>",
"   <p>",
"    This can be accomplished through the attachment of a stereotactic head frame using four pins that attach to the outer table of the skull (",
"    <a class=\"graphic graphic_figure graphicRef80796 \" href=\"mobipreview.htm?9/46/9956\">",
"     figure 2",
"    </a>",
"    ). The head frame placement is usually done with local anesthesia, although sedation may be required. This method is typically used for SRS using x-ray or gamma ray radiation (photon radiation).",
"   </p>",
"   <p>",
"    Alternatively, a non-invasive frame can be used in conjunction with skeletally fixed fiducials, which radiographically guide the highly precise targeting necessary for proton radiosurgical treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32855/abstract/27\">",
"     27",
"    </a>",
"    ]. Other frameless, image-guided stereotactic systems also have been developed for use with x-ray radiation sources. These include the CyberKnife and the Novalis ExacTrac S-Ray 6 D systems. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'CyberKnife'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H19\">",
"     'Novalis ExacTrac Robotic system'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    With these systems, motion is minimized by application of individualized non-invasive head masks even though the cranium is not immobilized with a rigid head frame. The small amount of head motion is detected by the use of an infrared camera and corrected prior to treatment. These corrections are not instantaneous, and the lag time between motion detection and radiation administration remains a source of inaccuracy. As such, invasive frame or skeletal fiducial based methodologies remain preferable for the highest precision radiosurgery treatments. This is particularly relevant for patients with small benign lesions and a long life expectancy (such as vestibular schwannoma) and. Frameless radiosurgery is a reasonable option for palliative treatment of malignant disease, larger lesions, and multifraction treatments.",
"   </p>",
"   <p>",
"    After placement of a head frame, high resolution computed tomography (CT) or magnetic resonance imaging (MRI) is obtained to visualize its four posts. Spatial coordinates for the lesion are calculated relative to these landmarks. During the RT session, the frame is bolted to the treatment couch to immobilize the patient, allowing precise targeting of the radiation. The patient is treated on the same day that the head frame is placed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Radiation delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both gamma rays and x-rays are photon radiation. As photons penetrate tissue, energy deposition decreases exponentially with depth below the surface and the radiation passes entirely through the tissue (",
"    <a class=\"graphic graphic_figure graphicRef72496 \" href=\"mobipreview.htm?18/38/19054\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50467 \" href=\"mobipreview.htm?32/46/33507\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Several different systems are available for photon-based SRS. The most widely used are the Gamma Knife and Linac, which have similar efficacy. This was illustrated in a multicenter clinical trial that combined SRS with whole brain RT for the treatment of brain metastases; no differences were observed in either efficacy or toxicity in patients treated with the two systems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32855/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Gamma Knife",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Gamma Knife system consists an array of more than 200 cobalt-60 sources surrounded by an 18,000 kg shield (",
"    <a class=\"graphic graphic_figure graphicRef72944 \" href=\"mobipreview.htm?26/36/27213\">",
"     figure 4",
"    </a>",
"    ). The sources are oriented such that all the beams converge at a single point termed the isocenter. This array produces a target accuracy between 0.1 and 1 mm, which is at least as good as the best possible lesion delineation with current imaging technology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32855/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During treatment, the patient is positioned so that the target coincides with the isocenter of the Gamma Knife unit. Using techniques of beam blocking, multiple or overlapping isocenters, and differential isocenter weighting, the radiation volume is approximated to that of the target lesion (",
"    <a class=\"graphic graphic_figure graphicRef72944 \" href=\"mobipreview.htm?26/36/27213\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Linac",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principles of a Linac (linear accelerator) are identical to those of the Gamma Knife. Instead of using an array of cobalt sources, Linac SRS utilizes multiple non-coplanar arcs of radiation that intersect at the target volume. As a result, radiation received by normal tissue in each beam path is minimal relative to the point of beam convergence. Linac-based devices also achieve target accuracy between 0.1 and 1 mm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32855/abstract/29\">",
"     29",
"    </a>",
"    ]. The radiation volume is carefully matched to the lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32855/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     CyberKnife",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CyberKnife device combines a mobile linear accelerator with an image-guided robotic system (",
"    <a class=\"graphic graphic_figure graphicRef82275 \" href=\"mobipreview.htm?8/30/8675\">",
"     figure 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32855/abstract/30\">",
"     30",
"    </a>",
"    ]. The mobility of the device, combined with real-time imaging, obviates the need for an invasive stereotactic head frame.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Novalis ExacTrac Robotic system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ExacTrac X-Ray 6D consists of two infrared (IR) cameras for patient tracking, two floor-mounted kilovolt x-ray tubes, and two ceiling-mounted detectors. X-ray images of the cranial skeletal anatomy are fused to the digital reconstructed radiographs derived from the treatment planning computed tomographic (CT) scan to facilitate patient positioning. Infrared fiducial markers attached to the patient allow precise tracking of patient's motion by the infrared camera. This information is transmitted to an integrated computer system that corrects for any motion by adjusting the position of the treatment couch prior to the radiation delivery. Target accuracy of approximately 1 mm is achieved.",
"   </p>",
"   <p>",
"    Prior to treatment, CT images are used to define the spatial relationship between the patient's bony anatomy and the target volume. During the actual treatment, patient movement is monitored with minimal time lag by the system's low dose x-ray cameras. These images are compared to radiographs derived from the pretreatment CT scan. Based upon these comparisons, the computer-controlled robotic arm adjusts the mobile linear accelerator in response to changes in patient position. A target accuracy of less than 1 mm is achieved without a stereotactic frame.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PROTON BEAM SRS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A proton beam is generated by stripping a hydrogen atom of its electron and accelerating the residual proton in a magnetic field [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32855/abstract/31\">",
"     31",
"    </a>",
"    ]. Charged protons have biologic properties that are different from a photon beam and offer advantages in selected situations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10968?source=see_link&amp;anchor=H2#H2\">",
"     \"Proton and ion beams in cancer therapy\", section on 'Rationale for clinical advantages'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dose distribution of a proton beam consists of an entrance region through which there is a slowly increasing dose, followed by a rapid rise to a maximum (the Bragg peak), and a fall to near zero (",
"    <a class=\"graphic graphic_figure graphicRef72496 \" href=\"mobipreview.htm?18/38/19054\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50467 \" href=\"mobipreview.htm?32/46/33507\">",
"     image 1",
"    </a>",
"    ). &nbsp;In contrast, the dose administered to tissue with a photon beam undergoes exponential decay with increasing tissue penetration.",
"   </p>",
"   <p>",
"    The depth of the Bragg peak is a function of the energy of the proton beam and is modulated so that the depth of penetration corresponds to the depth of the target beneath the surface. Because there is no energy deposition beyond the Bragg peak, tissues beyond the target receive no radiation exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32855/abstract/32\">",
"     32",
"    </a>",
"    ]. The Bragg peak itself is only millimeters in depth. In order to cover the entire axial diameter of a tumor, the energy of the beam is precisely varied as it is delivered to cover the entire lesion from front to back. This is known as the spread-out Bragg peak (",
"    <a class=\"graphic graphic_figure graphicRef72496 \" href=\"mobipreview.htm?18/38/19054\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50467 \" href=\"mobipreview.htm?32/46/33507\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, two to six beams are aimed at the target from different directions in sequence. This minimizes the dose of radiation received by normal tissue along the beam path from the surface to the intended target in each direction. Each of the beams is additionally shaped by brass collimators (apertures) that correspond to the cross-sectional silhouette of the tumor along the axis of that particular beam (",
"    <a class=\"graphic graphic_figure graphicRef56908 graphicRef68580 \" href=\"mobipreview.htm?27/36/28226\">",
"     figure 6A-B",
"    </a>",
"    ). Additionally each beam passes through a custom shaped bolus of absorbing material that modifies the energy of the protons across the face of the beam. This controls the energies of the individual protons so that the back edge of the Bragg peak conforms optimally to the three-dimensional shape of the target at its deep surface (",
"    <a class=\"graphic graphic_figure graphicRef56908 graphicRef68580 \" href=\"mobipreview.htm?27/36/28226\">",
"     figure 6A-B",
"    </a>",
"    ). All of these maneuvers together maximize the conformality of the radiation treatment volume in relation to the volume of the target being irradiated and absolutely minimize the dose of radiation to nearby normal tissues. This constitutes the physical advantage of proton radiation in contrast to photons (gamma or x-rays).",
"   </p>",
"   <p>",
"    An automated device, known as STAR (STereotactic Alignment for Radiosurgery), was developed to facilitate versatile and precise patient positioning (",
"    <a class=\"graphic graphic_figure graphicRef69137 \" href=\"mobipreview.htm?16/6/16482\">",
"     figure 7",
"    </a>",
"    ). The patient is placed in an immobilizing head frame attached to a couch apparatus that can be rotated relative to a fixed beam portal. Further refinements have utilized a mobile proton beam source (",
"    <a class=\"graphic graphic_picture graphicRef72402 \" href=\"mobipreview.htm?13/3/13364\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Same day treatments for proton SRS are not feasible because of the time required for preparation of the necessary equipment that must be fabricated for each patient and for quality assurance and control. To allow for this, we implant three small stainless steel beads into the outer surface of the skull through a needle. This 15 minute procedure using local anesthesia is done prior to a high resolution CT scan that identifies each of the markers in relation to the target to be treated. This information allows one to precisely localize the target at the time of proton beam treatment by using conventional x-rays for patient alignment. The patient immobilization during proton SRS is achieved using a modified Gill-Thomas-Cosman frame (",
"    <a class=\"graphic graphic_picture graphicRef70798 \" href=\"mobipreview.htm?40/19/41265\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Availability",
"    </span>",
"    &nbsp;&mdash;&nbsp;There currently are only a very limited number of proton treatment facilities worldwide, and less than half of these sites offer proton beam SRS. In contrast, photon-based SRS (Gamma Knife, Linac, CyberKnife) is widely available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32855/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of limited availability, patient selection for proton SRS is restricted to carefully defined indications. In general, small (&lt;10 cm3), spherically-shaped lesions do not require proton SRS if they are not located close to critical anatomic structures, in eloquent regions, in deep subcortical areas, or in previously irradiated volumes. In these cases, equally effective results can typically be attained with photon SRS. Patients with a limited expected survival are also unlikely to derive additional benefit from proton SRS, since delayed radiation toxicity from photon irradiation does not develop until years after treatment. In contrast, the advantage of protons with regard to conformality of the radiation dose (ie, minimizing radiation to normal tissues) becomes increasingly relevant with larger, irregularly shaped targets such as tumors and arteriovenous malformations, especially if they are intimately related to critical brain structures. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/42/26274?source=see_link\">",
"       \"Patient information: Arteriovenous malformations in the brain (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stereotactic radiosurgery (SRS) has emerged as an important option based upon advances in neuroimaging, medical physics, stereotactic neurosurgery, and radiation oncology. Its successful clinical application requires a team-based approach, with active collaboration between specialists from each of these fields.",
"   </p>",
"   <p>",
"    Careful consideration must be given by the team members regarding the relative merits of SRS, conventional fractionated RT, surgery, and observation. In cases where SRS is indicated, additional consideration must be given to whether proton SRS, if available, offers additional clinical benefits.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Chan A, Cardinale R, Loeffler J. Stereotactic irradiation. In: Perez CA, Brady LW, Halperin CA, Schmidt-Ullrich RK, Principles and practice of radiation oncology (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32855/abstract/2\">",
"      LEKSELL L. The stereotaxic method and radiosurgery of the brain. Acta Chir Scand 1951; 102:316.",
"     </a>",
"    </li>",
"    <li>",
"     Chan, A, Cardinale, R, Loeffler, J, Stereotactic irradiation. In: Principles and practice of radiation oncology, C. Perez, L. Brady, E. Halperin, and R. Schmidt-Ullrich, (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. p. 410.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32855/abstract/4\">",
"      Duma CM, Jacques D, Kopyov OV. The treatment of movement disorders using Gamma Knife stereotactic radiosurgery. Neurosurg Clin N Am 1999; 10:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32855/abstract/5\">",
"      Barnett GH, Linskey ME, Adler JR, et al. Stereotactic radiosurgery--an organized neurosurgery-sanctioned definition. J Neurosurg 2007; 106:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32855/abstract/6\">",
"      Bernier J, Hall EJ, Giaccia A. Radiation oncology: a century of achievements. Nat Rev Cancer 2004; 4:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32855/abstract/7\">",
"      Saleh-Gohari N, Helleday T. Conservative homologous recombination preferentially repairs DNA double-strand breaks in the S phase of the cell cycle in human cells. Nucleic Acids Res 2004; 32:3683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32855/abstract/8\">",
"      Kew Y, Levin VA. Advances in gene therapy and immunotherapy for brain tumors. Curr Opin Neurol 2003; 16:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32855/abstract/9\">",
"      McDermott MW, Sneed PK. Radiosurgery in metastatic brain cancer. Neurosurgery 2005; 57:S45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32855/abstract/10\">",
"      Szeifert GT, Atteberry DS, Kondziolka D, et al. Cerebral metastases pathology after radiosurgery: a multicenter study. Cancer 2006; 106:2672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32855/abstract/11\">",
"      Chang SD, Adler JR Jr, Martin DP. LINAC radiosurgery for cavernous sinus meningiomas. Stereotact Funct Neurosurg 1998; 71:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32855/abstract/12\">",
"      Nedzi LA, Kooy H, Alexander E 3rd, et al. Variables associated with the development of complications from radiosurgery of intracranial tumors. Int J Radiat Oncol Biol Phys 1991; 21:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32855/abstract/13\">",
"      Phillips MH, Frankel KA, Lyman JT, et al. Comparison of different radiation types and irradiation geometries in stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 1990; 18:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32855/abstract/14\">",
"      Shiau CY, Sneed PK, Shu HK, et al. Radiosurgery for brain metastases: relationship of dose and pattern of enhancement to local control. Int J Radiat Oncol Biol Phys 1997; 37:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32855/abstract/15\">",
"      Leber KA, Bergl&ouml;ff J, Langmann G, et al. Radiation sensitivity of visual and oculomotor pathways. Stereotact Funct Neurosurg 1995; 64 Suppl 1:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32855/abstract/16\">",
"      Leber KA, Bergl&ouml;ff J, Pendl G. Dose-response tolerance of the visual pathways and cranial nerves of the cavernous sinus to stereotactic radiosurgery. J Neurosurg 1998; 88:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32855/abstract/17\">",
"      Ito K, Kurita H, Sugasawa K, et al. Analyses of neuro-otological complications after radiosurgery for acoustic neurinomas. Int J Radiat Oncol Biol Phys 1997; 39:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32855/abstract/18\">",
"      Sakamoto T, Shirato H, Sato N, et al. Audiological assessment before and after fractionated stereotactic irradiation for vestibular schwannoma. Radiother Oncol 1998; 49:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32855/abstract/19\">",
"      Stafford SL, Pollock BE, Leavitt JA, et al. A study on the radiation tolerance of the optic nerves and chiasm after stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 2003; 55:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32855/abstract/20\">",
"      Tishler RB, Loeffler JS, Lunsford LD, et al. Tolerance of cranial nerves of the cavernous sinus to radiosurgery. Int J Radiat Oncol Biol Phys 1993; 27:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32855/abstract/21\">",
"      Lunsford LD, Niranjan A, Flickinger JC, et al. Radiosurgery of vestibular schwannomas: summary of experience in 829 cases. J Neurosurg 2005; 102 Suppl:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32855/abstract/22\">",
"      Eustacchio S, Trummer M, Fuchs I, et al. Preservation of cranial nerve function following Gamma Knife radiosurgery for benign skull base meningiomas: experience in 121 patients with follow-up of 5 to 9.8 years. Acta Neurochir Suppl 2002; 84:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32855/abstract/23\">",
"      Kreil W, Luggin J, Fuchs I, et al. Long term experience of gamma knife radiosurgery for benign skull base meningiomas. J Neurol Neurosurg Psychiatry 2005; 76:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32855/abstract/24\">",
"      Muthukumar N, Kondziolka D, Lunsford LD, Flickinger JC. Stereotactic radiosurgery for jugular foramen schwannomas. Surg Neurol 1999; 52:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32855/abstract/25\">",
"      Zhang N, Pan L, Dai JZ, et al. Gamma knife radiosurgery for jugular foramen schwannomas. J Neurosurg 2002; 97:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32855/abstract/26\">",
"      Flickinger JC, Kondziolka D, Lunsford LD, et al. Development of a model to predict permanent symptomatic postradiosurgery injury for arteriovenous malformation patients. Arteriovenous Malformation Radiosurgery Study Group. Int J Radiat Oncol Biol Phys 2000; 46:1143.",
"     </a>",
"    </li>",
"    <li>",
"     Chapman PH, Ogilvy CS, Butler WE. A New Stereotactic Alignment System for Charged-Particle Radiosurgery at the Harvard Cyclotron Laboratory, Boston. In: Stereotactic Radiosurgery, Alexander III E, Loeffler JS, Lunsford LD (Eds), McGraw-Hill, New York 1993. p.105.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32855/abstract/28\">",
"      Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004; 363:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32855/abstract/29\">",
"      Schwartz M. Stereotactic radiosurgery: comparing different technologies. CMAJ 1998; 158:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32855/abstract/30\">",
"      Kuo JS, Yu C, Petrovich Z, Apuzzo ML. The CyberKnife stereotactic radiosurgery system: description, installation, and an initial evaluation of use and functionality. Neurosurgery 2003; 53:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32855/abstract/31\">",
"      Lawrence, E, Edlefsen, N. On the production of high speed protons. Science 1930; 72:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32855/abstract/32\">",
"      Miller DW. A review of proton beam radiation therapy. Med Phys 1995; 22:1943.",
"     </a>",
"    </li>",
"    <li>",
"     Sisterson J. Particle Therapy Co-Operative Group (PTCOG). Particles Newsletter 2005; 35.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7063 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-49B032D4AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_5_32855=[""].join("\n");
var outline_f32_5_32855=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Fractionated (conventional) RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Stereotactic radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RADIOBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Fractionated RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Stereotactic radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Dose homogeneity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SRS VERSUS CONVENTIONAL RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Tumor volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Proximity to cranial nerves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Location of the lesion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Stereotactic guidance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Radiation delivery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Gamma Knife",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Linac",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - CyberKnife",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Novalis ExacTrac Robotic system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PROTON BEAM SRS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7063\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7063|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?32/46/33507\" title=\"diagnostic image 1\">",
"      Character photons b",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7063|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/57/28560\" title=\"figure 1\">",
"      Radiosurg radiother",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/46/9956\" title=\"figure 2\">",
"      Stereotactic headframe",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/38/19054\" title=\"figure 3\">",
"      Character photons a",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/36/27213\" title=\"figure 4\">",
"      Gamma knife LINAC radiosu",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/30/8675\" title=\"figure 5\">",
"      Cyber knife radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/50/23342\" title=\"figure 6A\">",
"      Collimaters comp a",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/6/11360\" title=\"figure 6B\">",
"      Collimaters comp b",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/6/16482\" title=\"figure 7\">",
"      STAR system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7063|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/3/13364\" title=\"picture 1\">",
"      Proton gantry system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/19/41265\" title=\"picture 2\">",
"      Gill-Thomas-Cosman frame",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/32/2566?source=related_link\">",
"      Complications of cranial stereotactic radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/42/26274?source=related_link\">",
"      Patient information: Arteriovenous malformations in the brain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10968?source=related_link\">",
"      Proton and ion beams in cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/21/43350?source=related_link\">",
"      Stereotactic body radiation therapy: Rationale and clinical experience",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44601?source=related_link\">",
"      Treatment of brain metastases in favorable prognosis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40232?source=related_link\">",
"      Vestibular schwannoma (acoustic neuroma)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_5_32856="Membranous EM II";
var content_f32_5_32856=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F62937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F62937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stage III membranous nephropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph in stage III membranous nephropathy. The subepithelial immune deposits (D) have a lucent, moth-eaten appearance and have been incorporated into the glomerular basement membrane (GBM) as new basement membrane has grown around the deposits (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Electron micrograph of a normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron dense deposits are present. Two normal platelets are seen in the capillary lumen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_5_32856=[""].join("\n");
var outline_f32_5_32856=null;
var title_f32_5_32857="Risperidone: Pediatric drug information";
var content_f32_5_32857=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Risperidone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"    see \"Risperidone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/27/21942?source=see_link\">",
"    see \"Risperidone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F218658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      RisperDAL&reg;;",
"     </li>",
"     <li>",
"      RisperDAL&reg; Consta&reg;;",
"     </li>",
"     <li>",
"      RisperDAL&reg; M-Tab&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F218659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Risperidone&reg;;",
"     </li>",
"     <li>",
"      Ava-Risperidone;",
"     </li>",
"     <li>",
"      CO Risperidone;",
"     </li>",
"     <li>",
"      Dom-Risperidone;",
"     </li>",
"     <li>",
"      JAMP-Risperidone;",
"     </li>",
"     <li>",
"      Mint-Risperidon;",
"     </li>",
"     <li>",
"      Mylan-Risperidone;",
"     </li>",
"     <li>",
"      Novo-Risperidone;",
"     </li>",
"     <li>",
"      PHL-Risperidone;",
"     </li>",
"     <li>",
"      PMS-Risperidone;",
"     </li>",
"     <li>",
"      PMS-Risperidone ODT;",
"     </li>",
"     <li>",
"      PRO-Risperidone;",
"     </li>",
"     <li>",
"      RAN&trade;-Risperidone;",
"     </li>",
"     <li>",
"      ratio-Risperidone;",
"     </li>",
"     <li>",
"      Risperdal&reg;;",
"     </li>",
"     <li>",
"      Risperdal&reg; Consta&reg;;",
"     </li>",
"     <li>",
"      Risperdal&reg; M-Tab&reg;;",
"     </li>",
"     <li>",
"      Riva-Risperidone;",
"     </li>",
"     <li>",
"      Sandoz-Risperidone;",
"     </li>",
"     <li>",
"      Teva-Risperidone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1055300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antipsychotic Agent, Atypical",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antipsychotic Agent, Benzisoxazole",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1055292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"      see \"Risperidone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Autism, associated irritability, including aggression, temper, tantrums, self-injurious behavior, and quickly changing moods:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;5 years and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     Individualize dose according to patient response and tolerability:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     15-20 kg: Oral: Initial: 0.25 mg/day; after &ge;4 days, may increase dose to 0.5 mg/day; maintain this dose for &ge;14 days. In patients not achieving sufficient clinical response, may increase dose in increments of 0.25 mg/day at &ge;2-week intervals. Doses ranging from 0.5-3 mg/day have been evaluated; however, therapeutic effect reached plateau at 1 mg/day in clinical trials. Following clinical response, consider gradually decreasing dose to lowest effective dose. May be administered once daily or in divided doses twice daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;20 kg: Oral: Initial: 0.5 mg/day; after &ge;4 days, may increase dose to 1 mg/day; maintain this dose for &ge;14 days. In patients not achieving sufficient clinical response, may increase dose in increments of 0.5 mg/day at &ge;2-week intervals. Doses ranging from 0.5-3 mg/day have been evaluated; however, therapeutic effect reached plateau at 2.5 mg/day (3 mg/day in pediatric patients &gt;45 kg) in clinical trials. Following clinical response, consider gradually decreasing to lowest effective dose. May be administered once daily or in divided doses twice daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Bipolar mania:",
"     </b>",
"     Children and Adolescents 10-17 years: Oral: Initial: 0.5 mg once daily; dose may be adjusted if needed, in increments of 0.5-1 mg/day at intervals &ge;24 hours, as tolerated, to a dose of 2.5 mg/day. Doses ranging from 0.5-6 mg/day have been evaluated; however, doses &gt;2.5 mg/day do not confer additional benefit and are associated with increased adverse events; doses &gt;6 mg/day have not been studied.",
"     <b>",
"      Note:",
"     </b>",
"     May administer",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     the daily dose twice daily in patients who experience persistent somnolence.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Delirium:",
"     </b>",
"     Limited data available; further studies are needed:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants &ge;4 months and Children &lt;5 years: Oral: Initial: 0.1-0.2 mg once daily at bedtime; dosing based on retrospective review of 10 pediatric patients (ages: 4 months to 16 years) which included three patients &lt;5 years of age (Schieveld, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;5 years and Adolescents: Oral: Initial: 0.2-0.5 mg once daily at bedtime; may titrate to lowest effective dose every 1-2 days; usual range: 0.2-2.5 mg/day in divided doses 2-4 times daily; maximum daily dose dependent upon patient weight: &lt;20 kg: 1 mg/day; 20-45 kg: 2.5 mg/day, &gt;45 kg: 3 mg/day (Karnik, 2007; Schieveld, 2007; Silver, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Disruptive behavior disorders (eg, conduct disorder, oppositional defiant disorder):",
"     </b>",
"     Limited data available: Children &ge;4 years and Adolescents: Oral: Initial: 0.01 mg/kg/dose once daily for 2 days, then 0.02 mg/kg/dose once daily, may further increase on weekly basis as tolerated to 0.06 mg/kg/dose once daily; usual maximum daily dose: 2 mg/",
"     <b>",
"      day",
"     </b>",
"     ; improvement in target symptoms typically within 1-4 weeks (Aman, 2002; Findling, 2004; Kutcher, 2004; Pandina, 2006).",
"     <b>",
"      Note:",
"     </b>",
"     May administer",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     the daily dose twice daily if breakthrough symptoms occur in the afternoon or evening.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Pervasive developmental disorders (PDD) (eg, disruptive behavior, aggression, irritability):",
"     </b>",
"     Limited data available: Children &ge;5 years and Adolescents: Oral: Initial: 0.01 mg/kg/dose once daily for 2 days, then 0.02 mg/kg/dose once daily; may further increase on weekly basis by &le;0.02 mg/kg/day increments as tolerated to 0.06 mg/kg/dose once daily; reported mean dose: 0.05 mg/kg/day (1.48 mg/day); other trials have reported similar optimal doses: 0.75-1.8 mg/day; improvement in target symptoms typically within 2-4 weeks (Fisman, 1996; McDougle, 1997; Shea, 2004).",
"     <b>",
"      Note:",
"     </b>",
"     May administer",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     the daily dose twice daily if breakthrough symptoms occur in the afternoon or evening.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Schizophrenia:",
"     </b>",
"     Adolescents 13-17 years: Oral: Initial: 0.5 mg once daily; dose may be adjusted if needed, in increments of 0.5-1 mg/day at intervals &ge;24 hours, as tolerated, to a dose of 3 mg/day. Doses ranging from 1-6 mg/day have been evaluated; however, doses &gt;3 mg/day do not confer additional benefit and are associated with increased adverse events.",
"     <b>",
"      Note:",
"     </b>",
"     May administer",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     the daily dose twice daily in patients who experience persistent somnolence.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Tourette syndrome, tics:",
"     </b>",
"     Limited data available: Children &ge;7 years and Adolescents: Oral: Initial: 0.25-0.5 mg once daily at night; may gradually titrate every 4-5 days in 0.25-0.5 mg increments to usual reported therapeutic range: 0.25-6 mg/day divided in twice daily doses (Dion, 2002; Roessner, 2011; Scahill, 2003; Singer, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Note:",
"     </b>",
"     When reinitiating treatment after discontinuation, the initial titration schedule should be followed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Bipolar mania:",
"     </b>",
"     Oral: Initial: 2-3 mg/dose once daily; adjust dose as needed, by 1 mg/day increments at intervals &ge;24 hours; dosing range: 1-6 mg/day; no dosing recommendation available for treatment &gt;3 weeks duration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Bipolar I, maintenance:",
"     </b>",
"     I.M. (RisperDAL&reg; Consta&reg;): 25 mg every 2 weeks; if unresponsive, some may benefit from larger doses (37.5-50 mg); maximum dose: 50 mg every 2 weeks. Dosage adjustments should not be made more frequently than every 4 weeks. A lower initial dose of 12.5 mg may be appropriate in some patients (eg, demonstrated poor tolerability to other psychotropic medications).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Oral risperidone (or other antipsychotic) should be administered with the initial injection of RisperDAL&reg; Consta&reg; and continued for 3 weeks (then discontinued) to maintain adequate therapeutic plasma concentrations prior to main release phase of risperidone from injection site. When switching from depot administration to a short-acting formulation, administer short-acting agent in place of the next regularly scheduled depot injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Schizophrenia:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: Initial: 2 mg/day in 1-2 divided doses; may be increased by 1-2 mg/day at intervals &ge;24 hours to a recommended dosage range of 4-8 mg/day; may be given as a single daily dose once maintenance dose is achieved; daily dosages &gt;6 mg do not appear to confer any additional benefit and the incidence of extrapyramidal symptoms is higher than with lower doses. Further dose adjustments should be made in increments/decrements of 1-2 mg/day on a weekly basis. Dose range studied in clinical trials: 4-16 mg/day. Maintenance: Recommended dosage range: 2-8 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M.: (RisperDAL&reg; Consta&reg;): Initial: 25 mg every 2 weeks; if unresponsive, some may benefit from larger doses (37.5-50 mg); maximum dose: 50 mg every 2 weeks. Dosage adjustments should not be made more frequently than every 4 weeks. A lower initial dose of 12.5 mg may be appropriate in some patients (eg, demonstrated poor tolerability to psychotropic medications).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Oral risperidone (or other antipsychotic) should be administered with the initial injection of RisperDAL&reg; Consta&reg; and continued for 3 weeks (then discontinued) to maintain adequate therapeutic plasma concentrations prior to main release phase of risperidone from injection site. When switching from depot administration to a short-acting formulation, administer short-acting agent in place of the next regularly scheduled depot injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Children and Adolescents: There are no dosage adjustments provided in manufacturer's labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Oral: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Initial: 0.5 mg twice daily; increase (as tolerated) in increments of &le;0.5 mg twice daily; increases to dosages &gt;1.5 mg twice daily should be made at intervals of &ge;1 week; slower titration may be required in some patients. Clearance of the active moiety (sum of parent drug and active metabolite) is decreased by 60% in patients with moderate-to-severe renal disease (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute) compared to healthy subjects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     I.M.: Initiate with",
"     <b>",
"      oral",
"     </b>",
"     dosing (0.5 mg twice daily for 1 week, then 2 mg/day for 1 week); if tolerated, begin 25 mg",
"     <b>",
"      I.M.",
"     </b>",
"     every 2 weeks; continue oral dosing for 3 weeks after the first I.M. injection. An initial I.M. dose of 12.5 mg may also be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Children and Adolescents: There are no dosage adjustments provided in manufacturer's labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Oral: Child-Pugh Class C: Initial: 0.5 mg twice daily; increase (as tolerated) in increments of &le;0.5 mg twice daily; increases to dosages &gt;1.5 mg twice daily should be made at intervals of &ge;1 week; slower titration may be required in some patients. The mean free fraction of risperidone in plasma was increased by 35% in patients with hepatic impairment compared to healthy subjects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     I.M.: Initiate with",
"     <b>",
"      oral",
"     </b>",
"     dosing (0.5 mg twice daily for 1 week, then 2 mg/day for 1 week); if tolerated, begin 25 mg",
"     <b>",
"      I.M.",
"     </b>",
"     every 2 weeks; continue oral dosing for 3 weeks after the first I.M. injection. An initial I.M. dose of 12.5 mg may also be considered.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F218631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, microspheres for reconstitution, extended release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RisperDAL&reg; Consta&reg;: 12.5 mg, 25 mg, 37.5 mg, 50 mg [contains polylactide-co-glycolide; supplied in a dose-pack containing vial with active ingredient in microsphere formulation, prefilled syringe with diluent, needle-free vial access device, and 2 safety needles (a 21 G UTW  1-inch and a 20 G TW 2-inch)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 1 mg/mL (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RisperDAL&reg;: 1 mg/mL (30 mL) [contains benzoic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RisperDAL&reg;: 0.25 mg, 0.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RisperDAL&reg;: 1 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RisperDAL&reg;: 2 mg, 3 mg, 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RisperDAL&reg; M-Tab&reg;: 0.5 mg [contains phenylalanine 0.14 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RisperDAL&reg; M-Tab&reg;: 1 mg [contains phenylalanine 0.28 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RisperDAL&reg; M-Tab&reg;: 2 mg [contains phenylalanine 0.42 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RisperDAL&reg; M-Tab&reg;: 3 mg [contains phenylalanine 0.63 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RisperDAL&reg; M-Tab&reg;: 4 mg [contains phenylalanine 0.84 mg/tablet]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F218617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes injection",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1055303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May be administered without regard to meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral solution: May administer directly from the manufacturer provided calibrated pipette or may mix with water, coffee, orange juice, or low-fat milk; do not mix with cola or tea;",
"     <b>",
"      Note:",
"     </b>",
"     Manufacturer provided calibrated pipette is calibrated in milligrams and milliliters; minimum calibrated volume: 0.25 mL; maximum calibrated volume: 3 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orally-disintegrating tablets: Do not remove tablet from blister pack until ready to administer; do not push tablet through foil (tablet may become damaged); peel back foil to expose tablet; use dry hands to remove tablet and place immediately on tongue; tablet will dissolve within seconds and may be swallowed with or without liquid; do not split or chew tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Before reconstitution, bring injection and diluent to room temperature; reconstitute with provided diluent only; shake vial vigorously for a minimum of 10 seconds to properly mix; suspension should appear thick, milky, and uniform; use immediately (or within 6 hours of reconstitution); if suspension settles prior to use, shake vigorously to resuspend. Administer deep I.M. into either the deltoid muscle or the upper-outer quadrant of the gluteal area; avoid inadvertent injection into blood vessel;",
"     <b>",
"      do not administer I.V.;",
"     </b>",
"     alternate injection site between the two arms or buttocks; do not combine two different dosage strengths into one single administration; administer with needle provided (1-inch needle for deltoid administration or 2-inch needle for gluteal administration); do not substitute any components of the dose pack.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1055295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral solution, tablet: Store at controlled room temperature 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F); protect from light; protect tablets from moisture; protect oral solution from freezing; do not store orally-disintegrating tablets once removed from blister unit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection: Store undiluted vials and diluent at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); protect from light; may store at room temperature &le;77&deg;F (25&deg;C) for &le;7 days prior to reconstitution; reconstituted suspension must be used within 6 hours.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1055302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Management of schizophrenia (FDA approved in ages &ge;13 years and adults); treatment of acute mania or mixed episodes associated with bipolar I disorder (FDA approved as monotherapy in ages &ge;10 years and adults; FDA approved in combination with lithium or valproate in adults); treatment of irritability (including aggression, temper tantrums, self-injurious behavior, and quickly changing moods) associated with autistic disorder in children and adolescents (FDA approved in ages 5-16 years); has also been used for treatment of Tourette syndrome (tics), disruptive behavior disorders, and delirium and irritability in the management of pervasive development disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Management of schizophrenia (FDA approved in adults); maintenance treatment of bipolar I disorder as monotherapy or in combination with lithium or valproate (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F218713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       RisperiDONE may be confused with reserpine, rOPINIRole",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       RisperDAL&reg; may be confused with lisinopril, reserpine, Restoril&trade;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F218711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Atrioventricular block first degree, bradycardia, bundle branch block, chest pain, ECG changes, facial edema, hypertension, hypotension, orthostatic hypotension, palpitation, peripheral edema, QT prolongation, syncope, tachycardia (more common in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: agitation, akathisia, akinesia, anxiety, attention span decreased, coordination impaired, depression, dizziness, fatigue (more common in children), fever (more common in children), gait disturbance, headache, hypoesthesia, insomnia, lethargy, malaise, nervousness, pain, parkinsonism (more common in children), postural dizziness, sedation (more common in children), seizure, sleep disturbances, sluggishness, somnolence (more common in adults), vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, dry skin, eczema, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast discomfort, ejaculation disorder/delayed, erectile dysfunction, galactorrhea, gynecomastia, hyperglycemia, hyperprolactinemia, libido decreased, menorrhea, menstrual irregularities, sexual dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (more common in children), anorexia, appetite decreased, appetite increased (more common in children), constipation, diarrhea, drooling (more common in children), dyspepsia, gastritis, gastroenteritis, nausea, salivation increased, toothache, vomiting (more common in children), weight gain (&ge;7% kg increase from baseline; more common in children), weight loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Cystitis, enuresis (more common in children), glucosuria, urinary incontinence (more common in children), urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, neutropenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased, GGT increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Abscess; injection site induration, pain, reaction, swelling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, buttock pain, creatine phosphokinase increased, dysarthria, dyskinesia (more common in adults), dystonia, hypokinesia, limb pain, musculoskeletal chest pain, myalgia, neck pain, paresthesia, posture abnormal, tardive dyskinesia, tremor (more common in adults), weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, conjunctivitis, visual acuity reduced",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Earache, otitis media",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchitis, cough (more common in children), dyspnea, epistaxis, nasal congestion, nasopharyngitis (more common in children), pharyngitis, pharyngolaryngeal pain, pneumonia, respiratory infection, rhinitis, rhinorrhea (more common in children), sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome, hypersensitivity, infection, thirst (more common in children), viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acarodermatitis, agranulocytosis, allergic reaction, alopecia, anaphylactic reaction, angioedema, antidiuretic hormone disorder, apnea, aspiration, atrial fibrillation, cerebral ischemia, cerebrovascular accident, cholestatic hepatitis, cholesterol increased, cholinergic syndrome, coma, cyst formation, delirium, diabetes mellitus, diabetic coma, diabetic ketoacidosis, diverticulitis, esophageal dysmotility, eye infection, eye swelling, fecal incontinence, fecaloma, glaucoma, granulocytopenia, hematoma, hemorrhage, hepatic failure, hepatocellular damage, hyperkeratosis, hypertonia, hypertriglyceridemia, hyperuricemia, hypoglycemia, hypokalemia, hyponatremia, hypothermia, intestinal obstruction, leukocytosis, leukopenia, leukorrhea, lower respiratory tract infection, lymphadenopathy, mania, migraine, myocardial infarction, myocarditis, necrosis, neuroleptic malignant syndrome (NMS), nystagmus, ocular hyperemia, pancreatitis, Pelger-Hu&euml;t anomaly, pituitary adenomas, precocious puberty, premature atrial contractions, priapism, pulmonary embolism, RBC disorders, renal insufficiency, retinal artery occlusion, retrograde ejaculation, rhabdomyolysis, skin ulceration, ST depression, stroke, superficial phlebitis, synostosis, temperature regulation impairment, thrombocytopenia, thrombophlebitis, thrombotic thrombocytopenic purpura, tongue paralysis, torticollis, transient ischemic attack, urinary retention, ventricular extrasystoles, ventricular tachycardia, water intoxication, withdrawal syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1055306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to risperidone or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1055291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and decrease the dose in patients with renal or hepatic impairment. Use with caution in patients with breast cancer or other prolactin-dependent tumors; risperidone elevates prolactin levels to a greater degree than other antipsychotic agents; high levels of prolactin may reduce pituitary gonadotropin secretion; galactorrhea, amenorrhea, gynecomastia, impotence, decreased bone density may occur. Use with caution in children and adolescents; adverse effects due to elevated prolactin levels have been observed; long-term effects on growth or sexual maturation have not been evaluated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Risperidone may cause a higher than normal weight gain in children and adolescents; monitor growth (including weight, height, BMI, and waist circumference) in pediatric patients receiving risperidone; compare weight gain to standard growth curves. Risperidone may cause increases in metabolic indices (eg, serum cholesterol, triglycerides).",
"     <b>",
"      Note:",
"     </b>",
"     A prospective, nonrandomized cohort study followed 338 antipsychotic na&iacute;ve pediatric patients (age 4-19 years) for a median 10.8 weeks (range 10.5-11.2 weeks) and reported the following significant mean increases in weight in kg (and % change from baseline): Olanzapine: 8.5 kg (15.2%), quetiapine: 6.1 kg (10.4%), risperidone: 5.3 kg (10.4%), and aripiprazole: 4.4 kg (8.1%) compared to the control cohort: 0.2 kg (0.65%). Increases in metabolic indices (eg, serum cholesterol, triglycerides, glucose) were also reported; a significant increase in serum triglycerides of 9.7 mg/mL was observed for patients receiving risperidone. Biannual monitoring of cardiometabolic indices after the first 3 months of therapy is suggested (Correll, 2009).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with seizure disorders or patients with conditions that lower seizure threshold; seizures have been rarely reported. Use with caution in patients with concomitant illnesses that may affect hepatic metabolism or hemodynamic responses (eg, unstable cardiac disease, recent MI), Parkinson's disease, or dementia with Lewy Bodies; an increased sensitivity to antipsychotic medications and adverse effects have been reported. Use with caution in suicidal patients. Use with caution in those at risk of aspiration pneumonia; esophageal dysmotility and aspiration have been associated with antipsychotic agents. May cause orthostatic hypotension with resultant dizziness, tachycardia, or syncope (especially during initial dose titration); use with caution in patients with cardiovascular disease (heart failure, past MI, or myocardia ischemia), cerebrovascular disease, dehydration, hypovolemia, or other conditions which may predispose patients to hypotension; may cause hypotension when used with antihypertensive agents. May cause somnolence (dose-related), priapism (rarely), thrombotic thrombocytopenic purpura (case report), alteration of temperature regulation (use with caution in patients exposed to temperature extremes); may mask diseases or toxicity of other drugs due to antiemetic effects. Rare cases of hepatotoxicity have been reported (Kumra, 1997; McDougle, 2000).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Children may experience a higher frequency of certain adverse effects than adults, particularly fatigue (18% to 42% vs &le;3%), somnolence (12% to 67% vs &le;14%), fever (20% vs 2%), constipation (21% vs 9%), increased salivation (22% vs 3%), abdominal pain (18% vs 4%), and dry mouth (13% vs 4%).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Orally disintegrating tablets contain aspartame which is metabolized to phenylalanine and must be avoided or used with caution in patients with phenylketonuria.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1055290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . May cause neuroleptic malignant syndrome (symptoms include hyperpyrexia, altered mental status, muscle rigidity, autonomic instability, acute renal failure, rhabdomyolysis, and elevated CPK). May cause extrapyramidal reactions, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia (risk of these reactions is low relative to other neuroleptics, and is dose-dependent; to decrease risk of tardive dyskinesia: Use smallest dose and shortest duration possible; evaluate continued need periodically; risk of dystonia is increased with the use of high potency and higher doses of conventional antipsychotics and in males and younger patients; occurring in up to 18% of children). May cause hyperglycemia, which may be severe and include potentially fatal ketoacidosis or hyperosmolar coma; use with caution and monitor glucose closely in patients with diabetes mellitus (or with risk factors such as family history or obesity); measure fasting blood glucose at the beginning of therapy and periodically during therapy in these patients; monitor for symptoms of hyperglycemia in all patients treated with risperidone; measure fasting blood glucose in patients who develop symptoms. May alter cardiac conduction (low risk relative to other neuroleptics); QT prolongation and life-threatening arrhythmias have occurred with therapeutic doses of neuroleptics; use with caution in patients with conduction abnormalities.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, pre-existing low WBC or history of drug-induced leuko/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     An increased risk of death has been reported with the use of antipsychotics in elderly patients with dementia-related psychosis",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; most deaths seemed to be cardiovascular (eg, sudden death, heart failure) or infectious (eg, pneumonia) in nature; a higher risk of mortality was seen with the use of furosemide plus risperidone (compared to risperidone alone or compared with placebo plus furosemide). An increased incidence of cerebrovascular adverse events (eg, transient ischemic attack, stroke), including fatalities, has been reported with the use of risperidone in elderly patients with dementia-related psychosis. Risperidone is not approved for the treatment of patients with dementia-related psychosis",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Oral solution contains benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (\"gasping\") in neonates; avoid use of risperidone products containing benzoic acid in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites. Vehicle used in injectable product (polylactide-co-glycolide microspheres) has rarely been associated with retinal artery occlusion in patients with abnormal arteriovenous anastomosis (eg, patent foramen ovale).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F218697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major), CYP3A4 (minor), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F218625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): Antipsychotics (Atypical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).  Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson's disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of RisperiDONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May enhance the adverse/toxic effect of RisperiDONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the adverse/toxic effect of RisperiDONE. Management: Consider alternative diuretic therapy (e.g., thiazides) to more potent diuretics (e.g., furosemide) in elderly patients receiving risperidone. Patients who require use of more potent diuretic therapy should be closely monitored and adequately hydrated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paliperidone: RisperiDONE may enhance the adverse/toxic effect of Paliperidone.  Management: Additive paliperidone exposure is expected with this combination.  Consider using an alternative combination when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of RisperiDONE.",
"     <b>",
"      Exceptions:",
"     </b>",
"     FluvoxaMINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May enhance the adverse/toxic effect of RisperiDONE. Generalized edema has developed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: May increase the serum concentration of RisperiDONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1055309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food does not affect rate or extent of oral absorption; oral solution is not compatible with cola or tea",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F218627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2888768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     An increased risk of teratogenic effects was not observed in animal reproduction studies; however, an increase in pup mortality was observed following peri-postnatal exposure. In human studies, risperidone and its metabolite cross the placenta (Newport, 2007). An increased risk of teratogenic effects has not been observed following maternal use of risperidone (limited data) (Coppola, 2007).  Agenesis of the corpus callosum has been noted in one case report of an infant exposed",
"     <i>",
"      in utero",
"     </i>",
"     . Antipsychotic use during the third trimester of pregnancy has a risk for extrapyramidal symptoms (EPS) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor. These effects may be self-limiting and allow recovery within hours or days with no specific treatment, or they may be severe requiring prolonged hospitalization. When using Risperdal&reg; Consta&reg;, patients should notify healthcare provider if they become or intend to become pregnant during therapy or within 12 weeks of last injection. Risperidone may cause hyperprolactinemia, which may decrease reproductive function in both males and females.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     The ACOG recommends that therapy during pregnancy be individualized; treatment with psychiatric medications during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary healthcare provider, and pediatrician. Safety data related to atypical antipsychotics during pregnancy is limited and routine use is not recommended. However, if a woman is inadvertently exposed to an atypical antipsychotic while pregnant, continuing therapy may be preferable to switching to a typical antipsychotic that the fetus has not yet been exposed to; consider risk:benefit (ACOG, 2008).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Healthcare providers are encouraged to enroll women 18-45 years of age exposed to risperidone during pregnancy in the Atypical Antipsychotics Pregnancy Registry (1-866-961-2388 or file://www.womensmentalhealth.org/pregnancyregistry).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1055299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure (including orthostatic) and heart rate, particularly during dosage titration; mental status, abnormal involuntary movement scale (AIMS), and extrapyramidal symptoms; growth, BMI, waist circumference, and weight (in adults, weight should be assessed prior to treatment and at 4 weeks, 8 weeks, 12 weeks, and then at quarterly intervals; consider titrating to a different antipsychotic agent for a weight gain &ge;5% of the initial weight); CBC with differential; liver enzymes in children (especially obese children or those who are rapidly gaining weight while receiving therapy); lipid profile; fasting blood glucose/Hgb A",
"     <sub>",
"      1c",
"     </sub>",
"     (prior to treatment, at 3 months, then annually); prolactin serum concentrations",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1055289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Atypical antipsychotic (benzisoxazole derivative); highly potent serotonin and dopamine receptor antagonist; binds to 5-HT",
"     <sub>",
"      2",
"     </sub>",
"     -receptors in the CNS and in the periphery with a very high affinity; binds to dopamine-D",
"     <sub>",
"      2",
"     </sub>",
"     receptors, but with less affinity (~20 times lower). The addition of serotonin antagonism to dopamine antagonism (classic neuroleptic mechanism) is thought to improve negative symptoms of psychoses and reduce the incidence of extrapyramidal side effects. Alpha",
"     <sub>",
"      1",
"     </sub>",
"     , alpha",
"     <sub>",
"      2",
"     </sub>",
"     adrenergic, and histaminergic receptors are also antagonized with high affinity. Risperidone has low to moderate affinity for 5-HT",
"     <sub>",
"      1c",
"     </sub>",
"     , 5-HT",
"     <sub>",
"      1D",
"     </sub>",
"     , and 5-HT",
"     <sub>",
"      1A",
"     </sub>",
"     receptors, weak affinity for D",
"     <sub>",
"      1",
"     </sub>",
"     and no affinity for cholinergic muscarinic or beta",
"     <sub>",
"      1",
"     </sub>",
"     and beta",
"     <sub>",
"      2",
"     </sub>",
"     receptors",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1055305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Following oral administration, the pharmacokinetics of risperidone and 9-hydroxyrisperidone in children were found to be similar to values in adults (after adjusting for differences in body weight).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Initial: &lt;1% of dose released from microspheres; main release starts at &ge;3 weeks; release is maintained from 4-6 weeks; release ends by 7 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes into breast milk; breast milk to plasma ratio (n=1): Risperidone: 0.42; 9-hydroxyrisperidone: 0.24 (Hill, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : Risperidone: 1-2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Risperidone: 90%, plasma protein binding increases with increasing concentrations of alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein; 9-hydroxyrisperidone: 77%;",
"     <b>",
"      Note:",
"     </b>",
"     Risperidone free fraction may be increased by ~35% in patients with hepatic impairment due to decreased concentrations of albumin and alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive in the liver via cytochrome P450 CYP2D6 to 9-hydroxyrisperidone (major active metabolite); also undergoes N-dealkylation (minor pathway);",
"     <b>",
"      Note:",
"     </b>",
"     9-hydroxyrisperidone is the predominant circulating form and is approximately equal to risperidone in receptor binding activity; clinical effects are from combined concentrations of risperidone and 9-hydroxyrisperidone; clinically important differences between CYP2D6 poor and extensive metabolizers are not expected (pharmacokinetics of the sum of risperidone and 9-hydroxyrisperidone were similar in poor and extensive metabolizers)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 70%; tablet (relative to solution): 94%;",
"     <b>",
"      Note:",
"     </b>",
"     Orally-disintegrating tablets and oral solution are bioequivalent to tablets.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     IM: Deltoid I.M. injection is bioequivalent to gluteal I.M. injection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life (apparent):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Risperidone: Extensive metabolizers: 3 hours; poor metabolizers: 20 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     9-hydroxyrisperidone: Extensive metabolizers: 21 hours; poor metabolizers: 30 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Sum of risperidone and 9-hydroxyrisperidone: Overall mean: 20 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 3-6 days (due to extended release of drug from microspheres and subsequent absorption)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: Solution or tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Risperidone: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-hydroxyrisperidone: Extensive metabolizers: 3 hours; poor metabolizers: 17 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Excreted as risperidone and metabolites in urine (70%) and feces (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Moderate to severe renal impairment (sum of risperidone and 9-hydroxyrisperidone): Decreased by 60%",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1055297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/27/21942?source=see_link\">",
"      see \"Risperidone: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It may take several weeks to achieve desired results. Dilute solution with water, milk, or orange juice; do not dilute with beverages containing tannin or pectinate (eg, colas, tea). Maintain adequate hydration. May cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth; may cause postural hypotension, especially during initial dose titration (use caution when changing position from lying or sitting to standing).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Do not use other medications, nonprescription medications, and herbal or natural products without checking with prescriber or pharmacist; avoid alcohol and the herbal medicine, St John's wort. Report persistent CNS effects (eg, trembling fingers, altered gait or balance, excessive sedation, seizures, unusual muscle or skeletal movements), rapid heartbeat, palpitations, severe dizziness, fainting, swelling or pain in breasts (male and female), altered menstrual pattern, changes in urinary patterns, vision changes, skin rash, difficulty breathing, or worsening of condition to your physician.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1055307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-term usefulness of risperidone should be periodically re-evaluated in patients receiving the drug for extended periods of time. Risperdal&reg; Consta&reg; is a long-acting injection comprised of an extended release microsphere formulation; prior to injection, the microspheres are suspended in the provided diluent; the small polymeric microspheres degrade slowly, releasing the medication at a controlled rate.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aman MG, De Smedt G, Derivan A, et al, \"Double-Blind, Placebo-Controlled Study of Risperidone for the Treatment of Disruptive Behaviors in Children With Subaverage Intelligence,\"",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2002, 159(8):1337-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/5/32857/abstract-text/12153826/pubmed\" id=\"12153826\" target=\"_blank\">",
"        12153826",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity, \"Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes,\"",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2004, 27(2):596-601.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/5/32857/abstract-text/14747245/pubmed\" id=\"14747245\" target=\"_blank\">",
"        14747245",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bruggeman R, van der Linden C, Buitelaar JK, et al, \"Risperidone Versus Pimozide in Tourette's Disorder: A Comparative Double-Blind Parallel-Group Study,\"",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2001, 62(1):50-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/5/32857/abstract-text/11235929/pubmed\" id=\"11235929\" target=\"_blank\">",
"        11235929",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Correll CU, Manu P, Olshanskiy V, et al, \"Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2009, 302(16):1765-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/5/32857/abstract-text/19861668/pubmed\" id=\"19861668\" target=\"_blank\">",
"        19861668",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dion Y, Annable L, Sandor P, et al, \"Risperidone in the Treatment of Tourette Syndrome: A Double-Blind, Placebo-Controlled Trial,\"",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 2002, 22(1):31-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/5/32857/abstract-text/11799340/pubmed\" id=\"11799340\" target=\"_blank\">",
"        11799340",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Donfrancesco R, Calderoni D, and Vitiello B, \"Open-Label Amantadine in Children With Attention-Deficit/Hyperactivity Disorder,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2007, 17(5):657-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/5/32857/abstract-text/17979585/pubmed\" id=\"17979585\" target=\"_blank\">",
"        17979585",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Findling RL, Aman MG, Eerdekens M, et al, \"Long-Term, Open-Label Study of Risperidone in Children With Severe Disruptive Behaviors and Below-Average IQ,\"",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2004, 161(4):677-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/5/32857/abstract-text/15056514/pubmed\" id=\"15056514\" target=\"_blank\">",
"        15056514",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fisman S and Steele M, \"Use of Risperidone in Pervasive Developmental Disorders: A Case Series,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 1996, 6(3):177-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/5/32857/abstract-text/9231311 /pubmed\" id=\"9231311 \" target=\"_blank\">",
"        9231311",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fu-I L, Boarati MA, Stravogiannis A, et al, \"Use of Risperidone Long-Acting Injection to Support Treatment Adherence and Mood Stabilization in Pediatric Bipolar Patients: A Case Series,\"",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2009, 70(4):604-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/5/32857/abstract-text/19403102/pubmed\" id=\"19403102\" target=\"_blank\">",
"        19403102",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hill RC, McIvor RJ, Wojnar-Horton RE, et al, \"Risperidone Distribution and Excretion Into Human Milk: Case Report and Estimated Infant Exposure During Breast-Feeding,\"",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 2000, 20(2):285-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/5/32857/abstract-text/10770482/pubmed\" id=\"10770482\" target=\"_blank\">",
"        10770482",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ipser J and Stein DJ, \"Systematic Review of Pharmacotherapy of Disruptive Behavior Disorders in Children and Adolescents,\"",
"      <i>",
"       Psychopharmacology (Berl)",
"      </i>",
"      , 2007, 191(1):127-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/5/32857/abstract-text/16983542/pubmed\" id=\"16983542\" target=\"_blank\">",
"        16983542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Karnik NS, Joshi SV, Paterno C, et al, \"Subtypes of Pediatric Delirium: A Treatment Algorithm,\"",
"      <i>",
"       Psychosomatics",
"      </i>",
"      , 2007, 48(3):253-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/5/32857/abstract-text/17478595/pubmed\" id=\"17478595\" target=\"_blank\">",
"        17478595",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kumra S, Herion D, Jacobsen LK, et al, \"Case Study: Risperidone-Induced Hepatotoxicity in Pediatric Patients,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1997, 36(5):701-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/5/32857/abstract-text/9136506 /pubmed\" id=\"9136506 \" target=\"_blank\">",
"        9136506",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kutcher S, Aman M, Brooks SJ, et al, \"International Consensus Statement on Attention-Deficit/Hyperactivity Disorder (ADHD) and Disruptive Behaviour Disorders (DBDs): Clinical Implications and Treatment Practice Suggestions,\"",
"      <i>",
"       Eur Neuropsychopharmacol",
"      </i>",
"      , 2004, 14(1):11-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/5/32857/abstract-text/14659983/pubmed\" id=\"14659983\" target=\"_blank\">",
"        14659983",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lombroso PJ, Scahill L, King RA, et al, \"Risperidone Treatment of Children and Adolescents With Chronic Tic Disorders: A Preliminary Report,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1995, 34(9):1147-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/5/32857/abstract-text/7559308/pubmed\" id=\"7559308\" target=\"_blank\">",
"        7559308",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McDougle CJ, Holmes JP, Bronson MR, et al, \"Risperidone Treatment of Children and Adolescents With Pervasive Developmental Disorders: A Prospective Open-Label Study,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1997, 36(5):685-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/5/32857/abstract-text/9136504 /pubmed\" id=\"9136504 \" target=\"_blank\">",
"        9136504",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pandina GJ, Aman MG, and Findling RL, \"Risperidone in the Management of Disruptive Behavior Disorders,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2006, 16(4):379-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/5/32857/abstract-text/16958564/pubmed\" id=\"16958564\" target=\"_blank\">",
"        16958564",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roessner V, Plessen KJ, Rothenberger A, et al, \"European Clinical Guidelines for Tourette Syndrome and Other Tic Disorders. Part II: Pharmacological Treatment,\"",
"      <i>",
"       Eur Child Adolesc Psychiatry",
"      </i>",
"      , 2011, 20(4):173-96.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sandor P and Stephens RJ, \"Risperidone Treatment of Aggressive Behavior in Children With Tourette Syndrome,\"",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 2000, 20(6):710-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/5/32857/abstract-text/11106151/pubmed\" id=\"11106151\" target=\"_blank\">",
"        11106151",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scahill L, Leckman JF, Schultz RT, et al, \"A Placebo-Controlled Trial of Risperidone in Tourette Syndrome,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2003, 60(7):1130-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/5/32857/abstract-text/12682319/pubmed\" id=\"12682319\" target=\"_blank\">",
"        12682319",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schieveld JN, Leroy PL, van Os J, et al, \"Pediatric Delirium in Critical Illness: Phenomenology, Clinical Correlates and Treatment Response in 40 Cases in the Pediatric Intensive Care Unit,\"",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2007, 33(6):1033-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/5/32857/abstract-text/17457571/pubmed\" id=\"17457571\" target=\"_blank\">",
"        17457571",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shea S, Turgay A, Carroll A, et al, \"Risperidone in the Treatment of Disruptive Behavioral Symptoms in Children With Autistic and Other Pervasive Developmental Disorders,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(5):e634-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/5/32857/abstract-text/15492353/pubmed\" id=\"15492353\" target=\"_blank\">",
"        15492353",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silver GH, Kearney JA, Kutko MC, et al, \"Infant Delirium in Pediatric Critical Care Settings,\"",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2010, 167(10):1172-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/5/32857/abstract-text/20889664/pubmed\" id=\"20889664\" target=\"_blank\">",
"        20889664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singer HS, \"Treatment of Tics and Tourette Syndrome,\"",
"      <i>",
"       Curr Treat Options Neurol",
"      </i>",
"      , 2010, 12(6):539-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/5/32857/abstract-text/20848326/pubmed\" id=\"20848326\" target=\"_blank\">",
"        20848326",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith HA, Fuchs DC, Pandharipande PP, et al, \"Delirium: An Emerging Frontier in the Management of Critically Ill Children,\"",
"      <i>",
"       Crit Care Clin",
"      </i>",
"      , 2009, 25(3):593-614.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/5/32857/abstract-text/19576533/pubmed\" id=\"19576533\" target=\"_blank\">",
"        19576533",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12770 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-708A4DD6E0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_5_32857=[""].join("\n");
var outline_f32_5_32857=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709402\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218658\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218659\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055300\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055292\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218631\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218617\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055303\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055295\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055302\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218713\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218711\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055306\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055291\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055290\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218697\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218625\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055309\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218627\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2888768\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055299\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055289\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055305\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055297\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055307\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12770\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12770|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=related_link\">",
"      Risperidone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/27/21942?source=related_link\">",
"      Risperidone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_5_32858="Definition; epidemiology; and etiology of obesity in children and adolescents";
var content_f32_5_32858=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Definition; epidemiology; and etiology of obesity in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/5/32858/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/5/32858/contributors\">",
"     William J Klish, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/5/32858/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/5/32858/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/5/32858/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/5/32858/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/5/32858/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/5/32858/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity has become one of the most important public health problems in the United States&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. As the prevalence of obesity increased, so did the prevalence of the comorbidities associated with obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/4\">",
"     4",
"    </a>",
"    ]. For this reason it is imperative that health care providers identify overweight and obese children so that counseling and treatment can be provided.",
"   </p>",
"   <p>",
"    The definition, epidemiology, and etiology of obesity in children and adolescents will be presented here. Comorbidities of obesity in children and adolescents and the clinical evaluation of the obese child or adolescent are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/50/37674?source=see_link\">",
"     \"Comorbidities and complications of obesity in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/11/8378?source=see_link\">",
"     \"Clinical evaluation of the obese child and adolescent\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Overweight\" technically refers to an excess of body weight, whereas \"obesity\" refers to an excess of fat. However, the methods used to directly measure body fat are not available in daily practice. For this reason, obesity is often assessed by means of indirect estimates of body fat (ie, anthropometrics) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The body mass index (BMI) is the accepted standard measure of overweight and obesity for children two years of age and older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/6\">",
"     6",
"    </a>",
"    ]. BMI provides a guideline for weight in relation to height and is equal to the body weight (in kilograms) divided by the height (in meters) squared (",
"    <a class=\"graphic graphic_table graphicRef71431 \" href=\"mobipreview.htm?0/28/459\">",
"     table 1",
"    </a>",
"    ). Other measures of childhood obesity, including weight-for-height (which is particularly useful for the child younger than two years), measures of regional fat distribution (eg, waist circumference and waist-to-hip ratio), and the growth standards developed by the World Health Organization (WHO), are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/38/6760?source=see_link\">",
"     \"Measurement of body composition in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/14/31976?source=see_link&amp;anchor=H2#H2\">",
"     \"Measurement of growth in children\", section on 'Growth standards'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adults with a BMI between 25 and 30 are considered overweight; those with a BMI &ge;30 are considered to be obese. Unlike adults, children grow in height as well as weight. Thus, the norms for BMI in children vary with age and sex. In 2000, the National Center for Health Care Statistics and the Centers for Disease Control (CDC) published BMI reference standards for children between the ages of 2 and 20 years (",
"    <a class=\"graphic graphic_figure graphicRef60784 graphicRef68478 \" href=\"mobipreview.htm?10/0/10247\">",
"     figure 1A-B",
"    </a>",
"    ). BMI percentiles also can be determined using a calculator for boys (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?35/14/36070?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) and for girls (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?34/60/35782?source=see_link\">",
"     calculator 2",
"    </a>",
"    ). As children approach adulthood, the 85th and 95th percentile BMI for age and sex are approximately 25 and 30, the thresholds for overweight and obesity in adults, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A growing consensus supports the following definitions for children between 2 and 20 years of age (",
"    <a class=\"graphic graphic_table graphicRef78725 \" href=\"mobipreview.htm?23/40/24203\">",
"     table 2",
"    </a>",
"    ): &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Underweight",
"      </strong>",
"      &ndash; BMI &lt;5th percentile for age and sex.",
"     </li>",
"     <li>",
"      <strong>",
"       Normal weight",
"      </strong>",
"      &ndash; BMI between the 5th and 85th percentile for age and sex.",
"     </li>",
"     <li>",
"      <strong>",
"       Overweight",
"      </strong>",
"      &ndash; BMI between the 85th and 95th percentile for age and sex.",
"     </li>",
"     <li>",
"      <strong>",
"       Obese",
"      </strong>",
"      &ndash; BMI &ge;95th percentile for age and sex.",
"     </li>",
"     <li>",
"      <strong>",
"       Severe obesity",
"      </strong>",
"      &ndash; BMI &ge;120 percent of the 95th percentile values, OR a BMI &ge;35. This corresponds to approximately the 99th percentile, or BMI Z-score &ge;2.33 (ie, 2.33 standard deviations above the mean) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/8,9\">",
"       8,9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The definition of severe obesity in children and adolescents is not fully standardized. The above definition has been proposed because it is clinically practical, and the CDC growth standards are not sufficiently precise to use percentile curves at the extremes. At age 18, a BMI &ge;120 percent of the 95th percentile corresponds approximately to the BMI threshold of 35",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    which defines Class II obesity in adults (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/20/12615?source=see_link\">",
"     \"Screening for and clinical evaluation of obesity in adults\"",
"    </a>",
"    ). Children with severe obesity represent approximately four percent of children and adolescents in the United States, with the highest prevalence in Black and Mexican-American youth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. This group has significantly more cardiovascular risk factors and a greater risk for having obesity in adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/10\">",
"     10",
"    </a>",
"    ]. Therefore, this threshold appears to define a group with medically significant obesity in children and adolescents. Adolescents with this severe degree of obesity should be treated with tertiary care intervention with a multidisciplinary pediatric weight management team, which may include consideration for weight loss surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/47/16122?source=see_link\">",
"     \"Surgical management of severe obesity in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term \"morbid obesity\" is sometimes used to identify individuals with obesity-related comorbidities. However, this term is often inappropriately used as a synonym for severe obesity, and it also may have pejorative connotations to patients, so its use is discouraged. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/50/37674?source=see_link\">",
"     \"Comorbidities and complications of obesity in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the discussion that follows, the term \"obesity\" refers to children with BMI &gt;95 percentile for age and sex and \"overweight\" refers to children with BMI between the 85th and 95th percentile for age and sex, unless otherwise noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"   </p>",
"   <p>",
"    Currently, almost one third of children and adolescents in the United States are either overweight or obese [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/13\">",
"     13",
"    </a>",
"    ]. The population is distributed into higher weight categories with advancing age, as shown below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overweight or obese (body mass index [BMI] &ge;85 percentile)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; 26.7 percent of preschool children (2 to 5 years)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; 32.6 percent of school-aged children (6 to 11 years)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; 33.6 percent of adolescents (12 to 19 years)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obese (BMI &ge;95 percentile)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; 12.1 percent of preschool children",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; 18.0 percent of school-aged children",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; 18.4 percent of adolescents",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe obesity (defined as a BMI &ge;97 percentile for these data)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; 9.7 percent of preschool children",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; 13.0 percent of school-aged children",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; 13.0 percent of adolescents",
"   </p>",
"   <p>",
"    Childhood obesity is more common among American Indian, non-Hispanic blacks, and Mexican Americans than in non-Hispanic whites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/4,13-17\">",
"     4,13-17",
"    </a>",
"    ]. Having an obese parent increases the risk of obesity by two- to threefold. Obesity is also more prevalent among low-income populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/18\">",
"     18",
"    </a>",
"    ]. As an example, 14.9 percent of low-income preschool-aged children were obese in 2010, as compared with 12.1 percent in this age group in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/17\">",
"     17",
"    </a>",
"    ]. Among the low-income children, 2.1 percent had extreme obesity (BMI &ge;120 percent of the 95",
"    <sup>",
"     th",
"    </sup>",
"    percentile). In the same study, the prevalence of obesity among the low-income preschool-aged population increased from 1998 to 2003, but plateaued between 2003 and 2010.",
"   </p>",
"   <p>",
"    The prevalence of childhood overweight and obesity is also increasing in most other developed countries worldwide (",
"    <a class=\"graphic graphic_figure graphicRef68479 \" href=\"mobipreview.htm?3/4/3151\">",
"     figure 2",
"    </a>",
"    ). It is difficult to directly compare prevalence rates between countries because of differences in definitions and dates of measurements. Use of the International Obesity Task Force (IOTF) standards typically results in lower prevalence estimates than other standards [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. However, studies using comparable statistics show that rates are particularly high (greater than 30 percent) in most countries in North and South America, as well as in Great Britain, Greece, Italy, Malta, Portugal, and Spain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/21\">",
"     21",
"    </a>",
"    ]. There are somewhat lower rates in the Nordic countries, and the central portion of Western Europe. In Russia and most of the countries of Eastern Europe the prevalence of overweight is lower (less than 10 percent), but increasing. In China, the prevalence of overweight among children is approximately",
"    <span class=\"nowrap\">",
"     1/3",
"    </span>",
"    of that in the US, but a greater proportion of pre-school-aged children are affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, across a wide range of developed and developing countries, and using a variety of measures, studies show increasing prevalence of obesity in children. Small studies show reversal of the trend in a few populations since 2000, including children in Scotland [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/22\">",
"     22",
"    </a>",
"    ], and El Paso, Texas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/23\">",
"     23",
"    </a>",
"    ]. The reasons for the apparent improvement are not addressed in these studies.",
"   </p>",
"   <p>",
"    The increased prevalence of childhood obesity has resulted in an increased prevalence of the comorbidities associated with obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/4\">",
"     4",
"    </a>",
"    ]. As an example, the prevalence of conditions such as sleep apnea and gall bladder disease in US children and adolescents tripled between 1979 and 1981, and 1997 and 1999 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/24\">",
"     24",
"    </a>",
"    ]. Comorbidities of childhood obesity are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/50/37674?source=see_link\">",
"     \"Comorbidities and complications of obesity in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13797121\">",
"    <span class=\"h2\">",
"     Trends",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of obesity among school-aged children (6 to 11 years) and adolescents (12 to 19 years) in the United States dramatically increased between 1976-1980 and 2009-2010 (from 6.5 to 18.0 percent in children, and from 5.0 to 18.4 percent in adolescents) (",
"    <a class=\"graphic graphic_figure graphicRef62778 \" href=\"mobipreview.htm?11/30/11758\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/1,13\">",
"     1,13",
"    </a>",
"    ]. The prevalence of obesity also doubled for preschool-aged children (2 to 5 years) from 5 percent in 1976 to 1980 to 12.1 percent in 2009 to 2010. Among infants and toddlers, the prevalence of high weight for recumbent length was 9.7 percent in 2009 to 2010.",
"   </p>",
"   <p>",
"    Of note, the increase in obesity prevalence reached a plateau around 2000; the percentage of children and adolescents in each weight category remained approximately stable between 2000 and 2010 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/13\">",
"     13",
"    </a>",
"    ]. On subgroup analysis, a slight increasing trend in obesity prevalence and BMI was seen overall among adolescent boys, but not among girls. However, these data do not reflect the variability in trends for other subgroups, which vary among ethnic groups, age groups, and region. As an example, childhood obesity in California declined overall between 2001 and 2008, but continued to increase for Black and American Indian girls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/25\">",
"     25",
"    </a>",
"    ]. In New York City, obesity rates among children aged 5 to 14 years decreased from 21.9 percent in 2006-2007 to 20.7 percent in 2010-2011 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/26\">",
"     26",
"    </a>",
"    ]. Obesity also decreased to variable degrees in most ethnic and socioeconomic subgroups analyzed. Similar plateaus in the prevalence of childhood obesity are reported in population studies from Australia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/27\">",
"     27",
"    </a>",
"    ] and France [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/28\">",
"     28",
"    </a>",
"    ], and a decreasing trend among school-aged children in Switzerland [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/29\">",
"     29",
"    </a>",
"    ], among children younger than 6 years in Massachusetts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/30\">",
"     30",
"    </a>",
"    ], and among low-income preschool aged children in New York City and Los Angeles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Persistence into adulthood",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to predict which overweight children will become obese adults. The likelihood of persistence of childhood obesity into adulthood is related to age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/32-34\">",
"     32-34",
"    </a>",
"    ], parental obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/35-37\">",
"     35-37",
"    </a>",
"    ], and severity of obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In longitudinal studies, approximately 25 percent of obese preschool children remain obese as adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/40\">",
"     40",
"    </a>",
"    ], compared to approximately 50 percent of obese 6-year-olds, and 80 percent of obese 10- to 14-year-olds who had one obese parent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/35\">",
"     35",
"    </a>",
"    ]. In a large international cohort, 82 percent of individuals who were obese as children (age 11.4 &plusmn; 4.0 years) remained obese as adults at follow up approximately 23 years later [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/41\">",
"     41",
"    </a>",
"    ]. These statistics must be interpreted with caution since the dietary habits and activity levels of today's children may differ from those of the children in the studies, thereby altering the risk of obesity in adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/7\">",
"     7",
"    </a>",
"    ]. As a general rule, a sedentary obese child who does not alter his or her caloric intake and lifestyle is unlikely to be of normal weight as an adult.",
"   </p>",
"   <p>",
"    The severity of obesity during adolescence is an important predictor of whether the obesity is likely to persist into adulthood. In a large population study in the United States about 75 percent of adolescents with severe obesity (BMI &gt;120 percent of the 95",
"    <sup>",
"     th",
"    </sup>",
"    percentile) remained severely obese as adults (BMI &gt;40) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/42\">",
"     42",
"    </a>",
"    ]. Meanwhile, 8 percent of adolescents with more moderate obesity developed severe obesity as adults. In younger age groups, the severity of obesity also predicts the risk of persistent obesity, but to a lesser extent than in adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether gender affects the risk that obesity will persist into adulthood varies markedly among studies in different populations. In one study from 1980, approximately 80 percent of obese adolescent girls remained obese into adulthood, whereas approximately 30 percent of obese adolescent males did so [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/43\">",
"     43",
"    </a>",
"    ]. This was presumably related to changes in body composition that occur at puberty, when body fat decreases in boys and increases in girls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/44\">",
"     44",
"    </a>",
"    ]. However, in later cohorts, obesity in adolescent boys is more likely to be persistent, and the risk of persistent obesity is similar to that of girls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. In one study from Australia, both boys and girls who were obese during adolescence had a 50 to 60 percent chance of remaining obese as a young adult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/47\">",
"     47",
"    </a>",
"    ]. However, among adolescents who were overweight but not obese during adolescence, boys were more likely than girls to remain obese during young adulthood (15 versus 12 percent). &nbsp;",
"   </p>",
"   <p>",
"    The natural history of obesity and risk factors for persistence into adulthood is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3418?source=see_link&amp;anchor=H2#H2\">",
"     \"Etiology and natural history of obesity\", section on 'Age at which overweight develops'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology and pathogenesis of obesity are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3418?source=see_link\">",
"     \"Etiology and natural history of obesity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13929?source=see_link\">",
"     \"Pathogenesis of obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Environmental factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all obesity in children is strongly influenced by environmental factors, caused by either a sedentary lifestyle or a caloric intake that is greater than needs. The contributions of specific environmental influences are the subject of considerable discussion and research. Environmental factors explain only part of obesity risk, but are important targets for treatment because they are potentially modifiable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increasing trends in glycemic index of foods, sugar-containing beverages, portion sizes for prepared foods, fast food service, diminishing family presence at meals, decreasing structured physical activity, increasing use of computer-oriented play activity, and elements of the built environment (eg, availability of sidewalks and playgrounds) have all been considered as causal influences on the rise in obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/49\">",
"     49",
"    </a>",
"    ]. In particular, a number of well-designed studies have shown associations between intake of sugar-containing beverages or low physical activity and obesity or metabolic abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/50-57\">",
"     50-57",
"    </a>",
"    ]. Causal associations seem likely but are difficult to establish with certainty.",
"   </p>",
"   <p>",
"    Results of individual studies testing interventions to prevent childhood obesity are variable. It is difficult to draw firm conclusions from the literature because interventions tested vary in form and intensity, the populations studied are heterogeneous and subject to selection bias, and there are many potential unmeasured confounders that could affect weight outcomes. Moreover, it appears that effects of lifestyle interventions on body mass index (BMI) are small at best, with substantial variation, and thus are not detectable without very large sample sizes.",
"   </p>",
"   <p>",
"    Despite these limitations, a meta-analysis concluded that interventions to prevent childhood obesity are generally effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/58\">",
"     58",
"    </a>",
"    ]. Overall, children enrolled in intervention groups had a mean reduction in adiposity as compared to control groups (standardized mean difference in BMI or BMI z-score of -0.15",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    [95% CI -0.21 to -0.09]). While the effect size is small, this represents a clinically important difference across a population. The best supported strategies were school-based programs that enhance physical activity, nutrition education, and quality of food served at school, as well as parent-focused interventions designed to encourage children to be more active and reduce screen time. Studies targeting younger children (ages 6 to 12 years) were most effective. Because the intervention strategies and results varied widely among the included studies, the effect of each intervention component is not clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19815865\">",
"    <span class=\"h3\">",
"     Sugar-sweetened beverages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accumulating evidence suggests that consumption of sugar-sweetened beverages (including fruit juice) is an important contributor to the development of obesity in some individuals. according to nationally representative surveys of children in the United States, sugar-sweetened beverages supplied an average of 270",
"    <span class=\"nowrap\">",
"     kcal/day,",
"    </span>",
"    representing 10 to 15 percent of total caloric intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/59\">",
"     59",
"    </a>",
"    ]. Moreover, a randomized trial demonstrated that reducing consumption of sugar-sweetened beverages among overweight and obese adolescents is associated with a modest decrease in BMI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/60\">",
"     60",
"    </a>",
"    ]. In a separate randomized trial in 5- to 12-year-old children (primarily normal-weight), consumption of one serving of artificially sweetened beverage daily was associated with less weight gain and fat accumulation as compared with consumption of a sugar-sweetened beverage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/61\">",
"     61",
"    </a>",
"    ]. Finally, in a large observational study in adults, the association between obesity and sugar-sweetened beverages appeared to be mediated in part by genetic factors, which were quantified by a &ldquo;genetic-predisposition&rdquo; score, based on 32 BMI-associated loci [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In each of these studies, the observed effect sizes were small. Nonetheless, these findings support the concept that population-focused approaches to reduce intake of sugar-sweetened beverages, such as changes in school or public policy, could be beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/63-66\">",
"     63-66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One observational study found that dietary salt intake is associated with increased intake of sugar-sweetened beverages, perhaps because of increased thirst [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/67\">",
"     67",
"    </a>",
"    ]. The authors speculate that, if the relationship is causal, it is possible that salt-reduction strategies could help to reduce intake of sugar-sweetened beverages.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Television",
"    </span>",
"    &nbsp;&mdash;&nbsp;Television viewing is perhaps the best established environmental influence on the development of obesity during childhood. The amount of time spent in watching television is directly related to the prevalence of obesity in children and adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/68-72\">",
"     68-72",
"    </a>",
"    ]. The effects may persist into adulthood. In two longitudinal cohort studies, television viewing at &ge;5 years was independently associated with increased BMI at age 26 to 30 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Other studies suggest that the association between television viewing and obesity is considerably weaker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. There are several proposed mechanisms for this association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/78-81\">",
"     78-81",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Displacement of physical activity",
"     </li>",
"     <li>",
"      Depression of metabolic rate",
"     </li>",
"     <li>",
"      Adverse effects on diet quality",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One study provides evidence that the effects of television on obesity are mediated primarily by changes in energy intake. In a randomized trial, reducing television viewing and computer use among overweight four- to seven-year-old children was effective in reducing both BMI and energy intake during the two-year intervention, without apparent changes in physical activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/79\">",
"     79",
"    </a>",
"    ]. Similar associations between television viewing and energy intake have been shown in studies of older or non-overweight youth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Video games",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of electronic games also has been associated with obesity during childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/83\">",
"     83",
"    </a>",
"    ]. In the few studies that analyze the influences separately, the association with obesity is somewhat weaker for electronic games than for television [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/83,84\">",
"     83,84",
"    </a>",
"    ], perhaps because the games do not include food advertising.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12509546\">",
"    <span class=\"h3\">",
"     Exergames",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few video games have been specifically designed to provide nutritional education and encourage healthy habits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. Others require interactive physical activity by the player [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/87\">",
"     87",
"    </a>",
"    ]. Activity-enhancing games (\"exergames\") generally cause a small or moderate increase in energy expenditure during playing time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/88-92\">",
"     88-92",
"    </a>",
"    ]. Two studies examined some of the most commonly used games and found that energy expenditure of playing active games was higher than that of sedentary games, but not as high as playing the simulated sport itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/90,93\">",
"     90,93",
"    </a>",
"    ]. The energy expenditure depends on the game: in one study, energy expenditure during six different activity-enhancing games ranged 4.2 metabolic equivalents (mets) for Wii boxing to 7.1 mets for Sportwall, as compared with 4.9 mets for walking at 3",
"    <span class=\"nowrap\">",
"     miles/hour",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/94\">",
"     94",
"    </a>",
"    ]. A small study reported that use of one of these games had no long-term effect on obesity status, and that use of the game declined sharply over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/95\">",
"     95",
"    </a>",
"    ]. On the other hand, another report described good patient retention and clinically significant reductions in BMI among adolescent patients participating in a 10-week multifaceted obesity management program, which featured one-hour group exergaming sessions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/96\">",
"     96",
"    </a>",
"    ]. Otherwise, the efficacy of these games to increase physical activity or treat obesity has not been systematically studied. The long-term effect of activity-enhancing games probably depends on the intensity and participant enjoyment of the game, as well as the activities replaced by the gaming.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Sleep",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cross-sectional studies suggest an association between shortened sleep duration and obesity or insulin resistance, after adjustment for a number of potential environmental confounders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/49,97-101\">",
"     49,97-101",
"    </a>",
"    ]; the effects are more marked in children at the upper end of the weight range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/102\">",
"     102",
"    </a>",
"    ]. Similar findings have been seen in adult populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/103\">",
"     103",
"    </a>",
"    ]. Several longitudinal studies also showed associations after adjustment for confounders, suggesting that the association may be causal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/104-108\">",
"     104-108",
"    </a>",
"    ]. By contrast, another large longitudinal study using self-report measures of sleep patterns failed to find an association between short sleep duration during early childhood and subsequent development of childhood obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/109\">",
"     109",
"    </a>",
"    ]. Moreover, there is some evidence that sleep fragmentation and intermittent hypoxemia caused by sleep disordered breathing are associated with decreased insulin sensitivity in adolescents, independent of adiposity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/110,111\">",
"     110,111",
"    </a>",
"    ]. The mechanism for the possible association has not been established, but may include alterations in serum leptin and ghrelin levels, both of which have been implicated in the regulation of appetite, or perhaps a longer opportunity to ingest food. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3418?source=see_link&amp;anchor=H11#H11\">",
"     \"Etiology and natural history of obesity\", section on 'Sleep deprivation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of drugs can cause weight gain, including certain psychoactive drugs (particularly",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34185?source=see_link\">",
"     olanzapine",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=see_link\">",
"     risperidone",
"    </a>",
"    ), antiepileptic drugs, and glucocorticoids (",
"    <a class=\"graphic graphic_table graphicRef57541 \" href=\"mobipreview.htm?26/50/27436\">",
"     table 3",
"    </a>",
"    ). Brief courses of oral or inhaled glucocorticoids (eg, several days for an exacerbation of asthma) are unlikely to have long-term effects on body weight unless they are prescribed frequently. Weight gain and hyperlipidemia induced by olanzapine may be particularly severe in adolescents as compared to adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/112\">",
"     112",
"    </a>",
"    ]. Medication-induced weight gain is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3418?source=see_link&amp;anchor=H21#H21\">",
"     \"Etiology and natural history of obesity\", section on 'Drug-induced weight gain'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44760?source=see_link&amp;anchor=H28219059#H28219059\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\", section on 'Metabolic side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13986951\">",
"    <span class=\"h3\">",
"     Virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary evidence suggests the possibility that obesity can be triggered or exacerbated by exposure to a virus. Adenovirus 36 increases body fat in several animal models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/113\">",
"     113",
"    </a>",
"    ]. Human studies, including a small study in twins, have shown an association between adenovirus 36 antibodies and obesity status in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/114\">",
"     114",
"    </a>",
"    ]. A multicenter study in children and adolescents also showed an association between adenovirus 36 antibodies and the prevalence and severity of obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/115\">",
"     115",
"    </a>",
"    ]. Possible explanations for the observations in humans include a true causal association, vulnerability to adenovirus infection or persistence among individuals with obesity, or the presence of unmeasured confounders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3418?source=see_link&amp;anchor=H36#H36\">",
"     \"Etiology and natural history of obesity\", section on 'Infectious agents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39257?source=see_link&amp;anchor=H5438993#H5438993\">",
"     \"Epidemiology and clinical manifestations of adenovirus infection\", section on 'Possible association with obesity'",
"    </a>",
"    .) &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12793569\">",
"    <span class=\"h3\">",
"     Gut microbiota",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some investigators have suggested that there is a relationship between the resident bacteria within the intestinal tract and the potential for weight gain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/116-121\">",
"     116-121",
"    </a>",
"    ]. Studies in animals suggest the hypothesis that certain mixtures of resident bacteria have a greater potential for salvaging calories from the indigestible portion of the diet through fermentation, etc [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/122\">",
"     122",
"    </a>",
"    ]. If this is true, it is likely a minor contributor to the obesity epidemic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5397879\">",
"    <span class=\"h3\">",
"     Toxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary evidence suggests the possibility that obesity could be triggered or exacerbated by exposure to environmental endocrine disrupting chemicals, such as bisphenol A (BPA). BPA is a compound used to manufacture polycarbonate resin, and is a common contaminant of foods sold in cans and plastic packaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/123\">",
"     123",
"    </a>",
"    ]. Most individuals in the United States have detectable levels of BPA in urine, and most of the exposure is from food [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/124\">",
"     124",
"    </a>",
"    ]. Experimental studies in cell culture and animals suggest that BPA is a selective modulator of estrogen receptors, and accelerates adipogenesis and postnatal somatic growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/125-127\">",
"     125-127",
"    </a>",
"    ]. Epidemiologic studies in adults and children demonstrate an association between urinary BPA concentrations and obesity or obesity-related diseases, including diabetes and cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/128-131\">",
"     128-131",
"    </a>",
"    ]. It is possible that the observed association is due to dietary or environmental variables that were not included in the analysis, or by increased storage of BPA in adipose tissue among obese individuals, rather than a direct causal effect.",
"   </p>",
"   <p>",
"    Exposure to such endocrine disrupting chemicals could also be a mechanism for the &ldquo;metabolic programming&rdquo; phenomenon described below. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Metabolic programming'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic factors play a permissive role and interact with environmental factors to produce obesity. Studies suggest that heritable factors are responsible for 30 to 50 percent of the variation in adiposity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/132\">",
"     132",
"    </a>",
"    ], but most of the genetic polymorphisms responsible have not yet been isolated. Thus, genetic contributions to common obesity likely exist, but most of the molecular mechanisms for these factors have yet to be determined. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13929?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathogenesis of obesity\", section on 'Common obesity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of specific syndromes and single-gene defects which are linked to obesity in childhood have been identified (",
"    <a class=\"graphic graphic_table graphicRef70658 \" href=\"mobipreview.htm?23/24/23949\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef76948 \" href=\"mobipreview.htm?35/36/36428\">",
"     table 5",
"    </a>",
"    ). These are rare causes of obesity, accounting for less than one percent of childhood obesity in tertiary care centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/1,133,134\">",
"     1,133,134",
"    </a>",
"    ]. In addition to being overweight, children with genetic syndromes associated with obesity typically have early-onset obesity and characteristic findings on physical examination. These include dysmorphic features, short stature, developmental delay or intellectual disability (mental retardation), retinal changes, or deafness. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/8/134?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of Prader-Willi syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For most of the syndromes, including Prader-Willi syndrome, the genetic cause has been sufficiently isolated to permit specific testing, but the exact mechanism through which they cause obesity is not understood or is attributable to multiple genes (",
"    <a class=\"graphic graphic_table graphicRef70658 \" href=\"mobipreview.htm?23/24/23949\">",
"     table 4",
"    </a>",
"    ). Other disorders are attributable to a mutation in a single gene involved in regulation of body weight, although the mutations also may have effects on pigmentation (POMC) and the reproductive system (",
"    <a class=\"graphic graphic_table graphicRef82307 \" href=\"mobipreview.htm?8/4/8268\">",
"     table 6",
"    </a>",
"    ). Several of these affect the melanocortin pathway in the central nervous system. The most common single gene defect currently identified in populations with severe obesity are mutations in the melanocortin 4 receptor, but this is still rare, accounting for only about four to six percent of severe obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/135,136\">",
"     135,136",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Endocrine disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endocrine causes of obesity are identified in less than 1 percent of children and adolescents with obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/134\">",
"     134",
"    </a>",
"    ]. The disorders include hypothyroidism, cortisol excess (eg, the use of corticosteroid medication, Cushing syndrome), growth hormone deficiency, and pseudohypoparathyroidism, disorders which usually are associated with overweight or mild obesity rather than severe obesity (",
"    <a class=\"graphic graphic_table graphicRef63990 \" href=\"mobipreview.htm?14/60/15307\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/133,137,138\">",
"     133,137,138",
"    </a>",
"    ]. However, acquired hypothalamic lesions (eg, after surgery for a craniopharyngiomas, in the presence of a diencephalic tumor, or in association with congenital or acquired hypoventilation syndromes) may cause severe obesity, which is particularly difficult to treat.",
"   </p>",
"   <p>",
"    Case series have described a syndrome consisting of rapid onset obesity, hypothalamic dysfunction, hypoventilation, and autonomic dysregulation, without (ROHHAD) or with neural crest tumors (ROHHADNET). Patients may present in infancy or early childhood with central hypoventilation (resembling congenital central hypoventilation syndrome) and a variety of abnormalities in the hypothalamic-pituitary function axis (including Cushing-like features, growth hormone deficiency, precocious puberty, hyperprolactinemia, central hypothyroidism,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypernatremia with or without diabetes insipidus) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/139,140\">",
"     139,140",
"    </a>",
"    ]. Neural crest tumors, typically ganglioneuromas, were subsequently diagnosed in most of these cases (",
"    <a class=\"graphic graphic_table graphicRef88393 \" href=\"mobipreview.htm?2/0/2061\">",
"     table 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Most children with these problems have short stature",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypogonadism (",
"    <a class=\"graphic graphic_figure graphicRef87007 \" href=\"mobipreview.htm?42/17/43288\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/134\">",
"     134",
"    </a>",
"    ]. These disorders are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21865?source=see_link\">",
"     \"Acquired hypothyroidism in childhood and adolescence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/5/82?source=see_link\">",
"     \"Diagnosis of growth hormone deficiency in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Metabolic programming",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is increasing evidence that environmental and nutritional influences during critical periods in development can have permanent effects on an individual's predisposition to obesity and metabolic disease. The precise mediators and mechanisms for these effects have not been established, but are the subject of ongoing investigations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/141\">",
"     141",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Nutrition during gestation and early life",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal nutrition or endocrine profile during gestation is probably an important determinant of metabolic programming, as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individuals born small for gestational age (SGA) or large for gestational age (LGA) have higher rates of insulin resistance during childhood and young adulthood, even after controlling for obesity status [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/142-144\">",
"       142-144",
"      </a>",
"      ]. Similarly, many population-based studies confirm an association between birthweight (reflecting fetal nutrition) and later diabetes, heart disease, insulin resistance, and obesity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/145,146\">",
"       145,146",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Studies of a cohort of individuals exposed to the Dutch famine in 1944 to 1945, and controlled studies of over- and under-feeding in animals, support the notion that there are causal associations between nutritional exposures during gestation and later obesity and metabolic disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/147-149\">",
"       147-149",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A mother&rsquo;s prepregnancy weight and weight gain during pregnancy are important predictors of the child&rsquo;s birthweight, even after accounting for genetic and other prenatal environmental factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/144,150,151\">",
"       144,150,151",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study from Sweden, maternal diabetes mellitus during gestation was associated with an increased BMI in adult male offspring, independent of maternal BMI in early pregnancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/152\">",
"       152",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Children born to women who have had gastric bypass surgery appear to have a lower prevalence of obesity than those born before gastric bypass, suggesting that reversal of maternal obesity had beneficial permanent effects on the metabolic profile of the offspring [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/153\">",
"       153",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infancy and early childhood are probably also critical periods for metabolic programming. Studies in a variety of populations have shown consistent associations between rates of weight gain during infancy or early childhood and subsequent obesity or metabolic syndrome during early childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/154-156\">",
"     154-156",
"    </a>",
"    ], adolescence, or adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/157\">",
"     157",
"    </a>",
"    ] (for systematic reviews, see references [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/158-161\">",
"     158-161",
"    </a>",
"    ]), or with intermediate outcomes such as adiposity and blood pressure in early childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/162-164\">",
"     162-164",
"    </a>",
"    ]. In conjunction with the evidence supporting metabolic programming, these observations suggest that early intervention might be an important tool in preventing obesity.",
"   </p>",
"   <p>",
"    Controlled trials of early nutritional interventions with long-term outcomes are still lacking. Nonetheless, there is ample circumstantial evidence to support clinical efforts to optimize nutrition during gestation, infancy, and early childhood. Appropriate goals are to optimize glycemic control in pregnant women and target moderate rates of weight gain in infants and young children. Nutritional goals are less clear for low-birthweight infants, for whom catch-up growth is associated with improved neurodevelopmental outcomes, but also with increased risks for metabolic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/165-168\">",
"     165-168",
"    </a>",
"    ]. Increasing the protein component of feeding (eg, a maximum protein content of 3.6",
"    <span class=\"nowrap\">",
"     g/100",
"    </span>",
"    kcals) appears to normalize serum IGF-1 concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/165\">",
"     165",
"    </a>",
"    ]. This strategy has been proposed to achieve improved neurodevelopmental and metabolic outcomes for these infants, but it is not yet tested. Breastfeeding is no longer thought to have a significant independent protective effect on the development of obesity, although it has other benefits. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/47/32505?source=see_link&amp;anchor=H18#H18\">",
"     \"Infant benefits of breastfeeding\", section on 'Obesity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Other maternal endocrine factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other markers of the maternal endocrine milieu are also associated with childhood obesity, although the mechanisms for the association are not established. In a study of 6009 children and their mothers, younger age of the mother at menarche was an independent predictor of the child's obesity status, after adjustment for the maternal obesity status as well as socioeconomic factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/169\">",
"     169",
"    </a>",
"    ]. The children whose mothers had earlier menarche also had more rapid growth during the first two years of life, whereas birthweight and growth after two years were similar. The results of this study do not distinguish between mechanisms of metabolic programming versus genetic mechanisms for the transgenerational obesity transmission observed in this study. Environmental mechanisms are less likely because of the adjustment for maternal BMI and socioeconomic factors, but these cannot be excluded.",
"   </p>",
"   <p>",
"    A large longitudinal study failed to demonstrate intergenerational acceleration mechanisms (maternal-child transmission) from maternal weight status during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/5/32858/abstract/170\">",
"     170",
"    </a>",
"    ]. Among 4654 parent-child pairs, the father-offspring and mother-offspring associations for BMI were equally strong. Parental height and weight were self-reported during the pregnancy, and the child's BMI was measured at approximately 7.5 years of age. This study did not detect any effects of maternal obesity transmitted to the child through the intrauterine environment. Thus, if metabolic programming is a mechanism for intergenerational transmission of obesity, the effect is either subtle, or the mediators are more complex than maternal BMI. It is also possible that the study systematically under-estimated parental BMIs because measurements were self-reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/30/23010?source=see_link\">",
"       \"Patient information: My child is overweight (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14724295\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The body mass index (BMI) is the accepted standard measure of overweight and obesity for children two years of age and older. BMI provides a guideline for weight in relation to height and is equal to the body weight (in kilograms) divided by the height (in meters) squared (",
"      <a class=\"graphic graphic_table graphicRef71431 \" href=\"mobipreview.htm?0/28/459\">",
"       table 1",
"      </a>",
"      ). Reference standards vary by age and sex (",
"      <a class=\"graphic graphic_figure graphicRef60784 graphicRef68478 \" href=\"mobipreview.htm?10/0/10247\">",
"       figure 1A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children between 2 and 20 years of age, the following weight categories are used (",
"      <a class=\"graphic graphic_table graphicRef78725 \" href=\"mobipreview.htm?23/40/24203\">",
"       table 2",
"      </a>",
"      ): (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Overweight",
"      </strong>",
"      &ndash; BMI between the 85th and 95th percentile for age and sex.",
"     </li>",
"     <li>",
"      <strong>",
"       Obesity",
"      </strong>",
"      &ndash; BMI &ge;95th percentile for age and sex.",
"     </li>",
"     <li>",
"      <strong>",
"       Severe obesity",
"      </strong>",
"      &ndash; BMI &ge;120 percent of the 95th percentile values, OR a BMI &ge;35. This corresponds to approximately the 99th percentile, or BMI z-score &ge;2.33.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Currently, almost one third of children and adolescents in the United States are either overweight or obese. The prevalence of obesity among children and adolescents tripled from the late 1970s to 2000, and subsequently plateaued for most age and weight categories (",
"      <a class=\"graphic graphic_figure graphicRef62778 \" href=\"mobipreview.htm?11/30/11758\">",
"       figure 3",
"      </a>",
"      ). The prevalence of childhood overweight and obesity is also increasing in most other developed countries worldwide (",
"      <a class=\"graphic graphic_figure graphicRef68479 \" href=\"mobipreview.htm?3/4/3151\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The likelihood of persistence of childhood obesity into adulthood is related to age, parental obesity, and severity of obesity. Obesity is somewhat more likely to persist in girls than in boys. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Persistence into adulthood'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of environmental factors probably contribute to the development of obesity in children, including increasing trends in glycemic index of foods, sugar-containing beverages, larger portion sizes for prepared foods, fast food service, diminishing family presence at meals, decreasing structured physical activity, shortened sleep duration, and changes in elements of the built environment (eg, availability of sidewalks and playgrounds). Television viewing is one of the best established environmental influences on the development of obesity during childhood. For a few children, medications (eg, certain psychoactive drugs) have an important causal role (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Environmental factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic factors play a permissive role and interact with environmental factors to produce obesity. Studies suggest that heritable factors are responsible for 30 to 50 percent of the variation in adiposity, but most of the genetic polymorphisms responsible have not yet been isolated. A few specific syndromes and single-gene defects which are linked to obesity in childhood have been identified (",
"      <a class=\"graphic graphic_table graphicRef70658 \" href=\"mobipreview.htm?23/24/23949\">",
"       table 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef76948 \" href=\"mobipreview.htm?35/36/36428\">",
"       table 5",
"      </a>",
"      ). &nbsp;(See",
"      <a class=\"local\" href=\"#H12\">",
"       'Genetic factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endocrine causes of obesity are identified in less than 1 percent of children and adolescents with obesity. The disorders include hypothyroidism, cortisol excess (eg, the use of corticosteroid medication, Cushing syndrome), growth hormone deficiency, pseudohypoparathyroidism, and acquired hypothalamic lesions (eg, after surgery for a craniopharyngiomas, in the presence of a diencephalic tumor) (",
"      <a class=\"graphic graphic_table graphicRef63990 \" href=\"mobipreview.htm?14/60/15307\">",
"       table 7",
"      </a>",
"      ). Most children with these problems have short stature",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypogonadism. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Endocrine disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is increasing evidence to support a role for &ldquo;metabolic programming&rdquo; in the development of obesity. Metabolic programming refers to the concept that environmental and nutritional influences during critical periods in development, particularly during gestation, can have permanent effects on an individual's predisposition to obesity and metabolic disease. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Metabolic programming'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/1\">",
"      Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA 2002; 288:1728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/2\">",
"      Strauss RS, Pollack HA. Epidemic increase in childhood overweight, 1986-1998. JAMA 2001; 286:2845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/3\">",
"      Jolliffe D. Extent of overweight among US children and adolescents from 1971 to 2000. Int J Obes Relat Metab Disord 2004; 28:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/4\">",
"      Dietz WH, Robinson TN. Clinical practice. Overweight children and adolescents. N Engl J Med 2005; 352:2100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/5\">",
"      Flodmark CE, Lissau I, Moreno LA, et al. New insights into the field of children and adolescents' obesity: the European perspective. Int J Obes Relat Metab Disord 2004; 28:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/6\">",
"      Deurenberg P, Weststrate JA, Seidell JC. Body mass index as a measure of body fatness: age- and sex-specific prediction formulas. Br J Nutr 1991; 65:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/7\">",
"      Baker S, Barlow S, Cochran W, et al. Overweight children and adolescents: a clinical report of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2005; 40:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/8\">",
"      Flegal KM, Wei R, Ogden CL, et al. Characterizing extreme values of body mass index-for-age by using the 2000 Centers for Disease Control and Prevention growth charts. Am J Clin Nutr 2009; 90:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/9\">",
"      Gulati AK, Kaplan DW, Daniels SR. Clinical tracking of severely obese children: a new growth chart. Pediatrics 2012; 130:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/10\">",
"      Freedman DS, Mei Z, Srinivasan SR, et al. Cardiovascular risk factors and excess adiposity among overweight children and adolescents: the Bogalusa Heart Study. J Pediatr 2007; 150:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/11\">",
"      Skelton JA, Cook SR, Auinger P, et al. Prevalence and trends of severe obesity among US children and adolescents. Acad Pediatr 2009; 9:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/12\">",
"      Barlow SE, Expert Committee. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 2007; 120 Suppl 4:S164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/13\">",
"      Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA 2012; 307:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/14\">",
"      Anderson SE, Whitaker RC. Prevalence of obesity among US preschool children in different racial and ethnic groups. Arch Pediatr Adolesc Med 2009; 163:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/15\">",
"      Centers for Disease Control and Prevention (CDC). Obesity prevalence among low-income, preschool-aged children - United States, 1998-2008. MMWR Morb Mortal Wkly Rep 2009; 58:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/16\">",
"      Taveras EM, Gillman MW, Kleinman K, et al. Racial/ethnic differences in early-life risk factors for childhood obesity. Pediatrics 2010; 125:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/17\">",
"      Pan L, Blanck HM, Sherry B, et al. Trends in the prevalence of extreme obesity among US preschool-aged children living in low-income families, 1998-2010. JAMA 2012; 308:2563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/18\">",
"      Eagle TF, Sheetz A, Gurm R, et al. Understanding childhood obesity in America: linkages between household income, community resources, and children's behaviors. Am Heart J 2012; 163:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/19\">",
"      Neovius M, Linn&eacute; Y, Barkeling B, R&ouml;ssner S. Discrepancies between classification systems of childhood obesity. Obes Rev 2004; 5:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/20\">",
"      Wang Y. Cross-national comparison of childhood obesity: the epidemic and the relationship between obesity and socioeconomic status. Int J Epidemiol 2001; 30:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/21\">",
"      Janssen I, Katzmarzyk PT, Boyce WF, et al. Comparison of overweight and obesity prevalence in school-aged youth from 34 countries and their relationships with physical activity and dietary patterns. Obes Rev 2005; 6:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/22\">",
"      Mitchell RT, McDougall CM, Crum JE. Decreasing prevalence of obesity in primary schoolchildren. Arch Dis Child 2007; 92:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/23\">",
"      Hoelscher DM, Kelder SH, P&eacute;rez A, et al. Changes in the regional prevalence of child obesity in 4th, 8th, and 11th grade students in Texas from 2000-2002 to 2004-2005. Obesity (Silver Spring) 2010; 18:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/24\">",
"      Wang G, Dietz WH. Economic burden of obesity in youths aged 6 to 17 years: 1979-1999. Pediatrics 2002; 109:E81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/25\">",
"      Madsen KA, Weedn AE, Crawford PB. Disparities in peaks, plateaus, and declines in prevalence of high BMI among adolescents. Pediatrics 2010; 126:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/26\">",
"      Centers for Disease Control and Prevention (CDC). Obesity in K-8 students - New York City, 2006-07 to 2010-11 school years. MMWR Morb Mortal Wkly Rep 2011; 60:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/27\">",
"      Olds TS, Tomkinson GR, Ferrar KE, Maher CA. Trends in the prevalence of childhood overweight and obesity in Australia between 1985 and 2008. Int J Obes (Lond) 2010; 34:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/28\">",
"      Salanave B, Peneau S, Rolland-Cachera MF, et al. Stabilization of overweight prevalence in French children between 2000 and 2007. Int J Pediatr Obes 2009; 4:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/29\">",
"      Aeberli I, Ammann RS, Knabenhans M, et al. Decrease in the prevalence of paediatric adiposity in Switzerland from 2002 to 2007. Public Health Nutr 2010; 13:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/30\">",
"      Wen X, Gillman MW, Rifas-Shiman SL, et al. Decreasing prevalence of obesity among young children in Massachusetts from 2004 to 2008. Pediatrics 2012; 129:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/31\">",
"      Centers for Disease Control and Prevention (CDC). Obesity prevalence among low-income, preschool-aged children--New York City and Los Angeles County, 2003-2011. MMWR Morb Mortal Wkly Rep 2013; 62:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/32\">",
"      Guo SS, Roche AF, Chumlea WC, et al. The predictive value of childhood body mass index values for overweight at age 35 y. Am J Clin Nutr 1994; 59:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/33\">",
"      Power C, Lake JK, Cole TJ. Body mass index and height from childhood to adulthood in the 1958 British born cohort. Am J Clin Nutr 1997; 66:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/34\">",
"      Parsons TJ, Power C, Logan S, Summerbell CD. Childhood predictors of adult obesity: a systematic review. Int J Obes Relat Metab Disord 1999; 23 Suppl 8:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/35\">",
"      Whitaker RC, Wright JA, Pepe MS, et al. Predicting obesity in young adulthood from childhood and parental obesity. N Engl J Med 1997; 337:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/36\">",
"      Reilly JJ, Methven E, McDowell ZC, et al. Health consequences of obesity. Arch Dis Child 2003; 88:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/37\">",
"      Rudolf M. Predicting babies' risk of obesity. Arch Dis Child 2011; 96:995.",
"     </a>",
"    </li>",
"    <li>",
"     Whitlock EP, Williams SB, Gold R, et al. Screening and Interventions for Childhood Overweight: A Systematic Review for the US Preventive Services Task Force: Systematic Evidence Review. Agency for Healthcare Research and Quality, Rockville, MD, 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/39\">",
"      Power C, Lake JK, Cole TJ. Measurement and long-term health risks of child and adolescent fatness. Int J Obes Relat Metab Disord 1997; 21:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/40\">",
"      Garn SM, LaVelle M. Two-decade follow-up of fatness in early childhood. Am J Dis Child 1985; 139:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/41\">",
"      Juonala M, Magnussen CG, Berenson GS, et al. Childhood adiposity, adult adiposity, and cardiovascular risk factors. N Engl J Med 2011; 365:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/42\">",
"      The NS, Suchindran C, North KE, et al. Association of adolescent obesity with risk of severe obesity in adulthood. JAMA 2010; 304:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/43\">",
"      Garn SM, Cole PE. Do the obese remain obese and the lean remain lean? Am J Public Health 1980; 70:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/44\">",
"      Mellits ED, Cheek DB. The assessment of body water and fatness from infancy to adulthood. Monogr Soc Res Child Dev 1970; 35:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/45\">",
"      Deshmukh-Taskar P, Nicklas TA, Morales M, et al. Tracking of overweight status from childhood to young adulthood: the Bogalusa Heart Study. Eur J Clin Nutr 2006; 60:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/46\">",
"      Herman KM, Craig CL, Gauvin L, Katzmarzyk PT. Tracking of obesity and physical activity from childhood to adulthood: the Physical Activity Longitudinal Study. Int J Pediatr Obes 2009; 4:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/47\">",
"      Patton GC, Coffey C, Carlin JB, et al. Overweight and obesity between adolescence and young adulthood: a 10-year prospective cohort study. J Adolesc Health 2011; 48:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/48\">",
"      Plachta-Danielzik S, Kehden B, Landsberg B, et al. Attributable risks for childhood overweight: evidence for limited effectiveness of prevention. Pediatrics 2012; 130:e865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/49\">",
"      Anderson SE, Whitaker RC. Household routines and obesity in US preschool-aged children. Pediatrics 2010; 125:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/50\">",
"      Bremer AA, Auinger P, Byrd RS. Relationship between insulin resistance-associated metabolic parameters and anthropometric measurements with sugar-sweetened beverage intake and physical activity levels in US adolescents: findings from the 1999-2004 National Health and Nutrition Examination Survey. Arch Pediatr Adolesc Med 2009; 163:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/51\">",
"      Malik VS, Schulze MB, Hu FB. Intake of sugar-sweetened beverages and weight gain: a systematic review. Am J Clin Nutr 2006; 84:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/52\">",
"      Berkey CS, Rockett HR, Field AE, et al. Sugar-added beverages and adolescent weight change. Obes Res 2004; 12:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/53\">",
"      Ebbeling CB, Feldman HA, Osganian SK, et al. Effects of decreasing sugar-sweetened beverage consumption on body weight in adolescents: a randomized, controlled pilot study. Pediatrics 2006; 117:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/54\">",
"      Dowda M, Ainsworth BE, Addy CL, et al. Environmental influences, physical activity, and weight status in 8- to 16-year-olds. Arch Pediatr Adolesc Med 2001; 155:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/55\">",
"      Menschik D, Ahmed S, Alexander MH, Blum RW. Adolescent physical activities as predictors of young adult weight. Arch Pediatr Adolesc Med 2008; 162:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/56\">",
"      Levin S, Lowry R, Brown DR, Dietz WH. Physical activity and body mass index among US adolescents: youth risk behavior survey, 1999. Arch Pediatr Adolesc Med 2003; 157:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/57\">",
"      Drake KM, Beach ML, Longacre MR, et al. Influence of sports, physical education, and active commuting to school on adolescent weight status. Pediatrics 2012; 130:e296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/58\">",
"      Waters E, de Silva-Sanigorski A, Hall BJ, et al. Interventions for preventing obesity in children. Cochrane Database Syst Rev 2011; :CD001871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/59\">",
"      Wang YC, Bleich SN, Gortmaker SL. Increasing caloric contribution from sugar-sweetened beverages and 100% fruit juices among US children and adolescents, 1988-2004. Pediatrics 2008; 121:e1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/60\">",
"      Ebbeling CB, Feldman HA, Chomitz VR, et al. A randomized trial of sugar-sweetened beverages and adolescent body weight. N Engl J Med 2012; 367:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/61\">",
"      de Ruyter JC, Olthof MR, Seidell JC, Katan MB. A trial of sugar-free or sugar-sweetened beverages and body weight in children. N Engl J Med 2012; 367:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/62\">",
"      Qi Q, Chu AY, Kang JH, et al. Sugar-sweetened beverages and genetic risk of obesity. N Engl J Med 2012; 367:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/63\">",
"      Farley TA. The role of government in preventing excess calorie consumption: the example of New York City. JAMA 2012; 308:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/64\">",
"      Elbel B, Cantor J, Mijanovich T. Potential effect of the New York City policy regarding sugared beverages. N Engl J Med 2012; 367:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/65\">",
"      Turner L, Chaloupka FJ. Encouraging trends in student access to competitive beverages in US public elementary schools, 2006-2007 to 2010-2011. Arch Pediatr Adolesc Med 2012; 166:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/66\">",
"      Pomeranz JL, Brownell KD. Portion sizes and beyond--government's legal authority to regulate food-industry practices. N Engl J Med 2012; 367:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/67\">",
"      Grimes CA, Riddell LJ, Campbell KJ, Nowson CA. Dietary salt intake, sugar-sweetened beverage consumption, and obesity risk. Pediatrics 2013; 131:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/68\">",
"      Dietz WH Jr, Gortmaker SL. Do we fatten our children at the television set? Obesity and television viewing in children and adolescents. Pediatrics 1985; 75:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/69\">",
"      Gortmaker SL, Must A, Sobol AM, et al. Television viewing as a cause of increasing obesity among children in the United States, 1986-1990. Arch Pediatr Adolesc Med 1996; 150:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/70\">",
"      Kaur H, Choi WS, Mayo MS, Harris KJ. Duration of television watching is associated with increased body mass index. J Pediatr 2003; 143:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/71\">",
"      Berkey CS, Rockett HR, Gillman MW, Colditz GA. One-year changes in activity and in inactivity among 10- to 15-year-old boys and girls: relationship to change in body mass index. Pediatrics 2003; 111:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/72\">",
"      Blair NJ, Thompson JM, Black PN, et al. Risk factors for obesity in 7-year-old European children: the Auckland Birthweight Collaborative Study. Arch Dis Child 2007; 92:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/73\">",
"      Hancox RJ, Milne BJ, Poulton R. Association between child and adolescent television viewing and adult health: a longitudinal birth cohort study. Lancet 2004; 364:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/74\">",
"      Viner RM, Cole TJ. Television viewing in early childhood predicts adult body mass index. J Pediatr 2005; 147:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/75\">",
"      Marshall SJ, Biddle SJ, Gorely T, et al. Relationships between media use, body fatness and physical activity in children and youth: a meta-analysis. Int J Obes Relat Metab Disord 2004; 28:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/76\">",
"      Wake M, Hesketh K, Waters E. Television, computer use and body mass index in Australian primary school children. J Paediatr Child Health 2003; 39:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/77\">",
"      Wahi G, Parkin PC, Beyene J, et al. Effectiveness of interventions aimed at reducing screen time in children: a systematic review and meta-analysis of randomized controlled trials. Arch Pediatr Adolesc Med 2011; 165:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/78\">",
"      Ludwig DS, Gortmaker SL. Programming obesity in childhood. Lancet 2004; 364:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/79\">",
"      Epstein LH, Roemmich JN, Robinson JL, et al. A randomized trial of the effects of reducing television viewing and computer use on body mass index in young children. Arch Pediatr Adolesc Med 2008; 162:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/80\">",
"      Boyland EJ, Harrold JA, Kirkham TC, et al. Food commercials increase preference for energy-dense foods, particularly in children who watch more television. Pediatrics 2011; 128:e93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/81\">",
"      Lipsky LM, Iannotti RJ. Associations of television viewing with eating behaviors in the 2009 Health Behaviour in School-aged Children Study. Arch Pediatr Adolesc Med 2012; 166:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/82\">",
"      Epstein LH, Roemmich JN, Paluch RA, Raynor HA. Influence of changes in sedentary behavior on energy and macronutrient intake in youth. Am J Clin Nutr 2005; 81:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/83\">",
"      Stettler N, Signer TM, Suter PM. Electronic games and environmental factors associated with childhood obesity in Switzerland. Obes Res 2004; 12:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/84\">",
"      Kautiainen S, Koivusilta L, Lintonen T, et al. Use of information and communication technology and prevalence of overweight and obesity among adolescents. Int J Obes (Lond) 2005; 29:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/85\">",
"      Brown D. Playing to win: video games and the fight against obesity. J Am Diet Assoc 2006; 106:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/86\">",
"      Baranowski T, Baranowski J, Cullen KW, et al. Squire's Quest! Dietary outcome evaluation of a multimedia game. Am J Prev Med 2003; 24:52.",
"     </a>",
"    </li>",
"    <li>",
"     Dance Dance Revolution Ultramix 3. Konami, Tokyo, Japan www.musicineverydirection.com (Accessed on June 04, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/88\">",
"      Lanningham-Foster L, Jensen TB, Foster RC, et al. Energy expenditure of sedentary screen time compared with active screen time for children. Pediatrics 2006; 118:e1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/89\">",
"      Mellecker RR, McManus AM. Energy expenditure and cardiovascular responses to seated and active gaming in children. Arch Pediatr Adolesc Med 2008; 162:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/90\">",
"      Graf DL, Pratt LV, Hester CN, Short KR. Playing active video games increases energy expenditure in children. Pediatrics 2009; 124:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/91\">",
"      Biddiss E, Irwin J. Active video games to promote physical activity in children and youth: a systematic review. Arch Pediatr Adolesc Med 2010; 164:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/92\">",
"      O'Loughlin EK, Dugas EN, Sabiston CM, O'Loughlin JL. Prevalence and correlates of exergaming in youth. Pediatrics 2012; 130:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/93\">",
"      Graves L, Stratton G, Ridgers ND, Cable NT. Comparison of energy expenditure in adolescents when playing new generation and sedentary computer games: cross sectional study. BMJ 2007; 335:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/94\">",
"      Bailey BW, McInnis K. Energy cost of exergaming: a comparison of the energy cost of 6 forms of exergaming. Arch Pediatr Adolesc Med 2011; 165:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/95\">",
"      Madsen KA, Yen S, Wlasiuk L, et al. Feasibility of a dance videogame to promote weight loss among overweight children and adolescents. Arch Pediatr Adolesc Med 2007; 161:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/96\">",
"      Christison A, Khan HA. Exergaming for health: a community-based pediatric weight management program using active video gaming. Clin Pediatr (Phila) 2012; 51:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/97\">",
"      Chaput JP, Tremblay A. Does short sleep duration favor abdominal adiposity in children? Int J Pediatr Obes 2007; 2:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/98\">",
"      Flint J, Kothare SV, Zihlif M, et al. Association between inadequate sleep and insulin resistance in obese children. J Pediatr 2007; 150:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/99\">",
"      Sekine M, Yamagami T, Handa K, et al. A dose-response relationship between short sleeping hours and childhood obesity: results of the Toyama Birth Cohort Study. Child Care Health Dev 2002; 28:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/100\">",
"      Jiang F, Zhu S, Yan C, et al. Sleep and obesity in preschool children. J Pediatr 2009; 154:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/101\">",
"      Altenburg TM, Chinapaw MJ, van der Knaap ET, et al. Longer Sleep - Slimmer Kids: The ENERGY-Project. PLoS One 2013; 8:e59522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/102\">",
"      Bayer O, Rosario AS, Wabitsch M, von Kries R. Sleep duration and obesity in children: is the association dependent on age and choice of the outcome parameter? Sleep 2009; 32:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/103\">",
"      Cappuccio FP, Taggart FM, Kandala NB, et al. Meta-analysis of short sleep duration and obesity in children and adults. Sleep 2008; 31:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/104\">",
"      Lumeng JC, Somashekar D, Appugliese D, et al. Shorter sleep duration is associated with increased risk for being overweight at ages 9 to 12 years. Pediatrics 2007; 120:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/105\">",
"      Landhuis CE, Poulton R, Welch D, Hancox RJ. Childhood sleep time and long-term risk for obesity: a 32-year prospective birth cohort study. Pediatrics 2008; 122:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/106\">",
"      Touchette E, Petit D, Tremblay RE, et al. Associations between sleep duration patterns and overweight/obesity at age 6. Sleep 2008; 31:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/107\">",
"      Carter PJ, Taylor BJ, Williams SM, Taylor RW. Longitudinal analysis of sleep in relation to BMI and body fat in children: the FLAME study. BMJ 2011; 342:d2712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/108\">",
"      Ara&uacute;jo J, Severo M, Ramos E. Sleep duration and adiposity during adolescence. Pediatrics 2012; 130:e1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/109\">",
"      Hiscock H, Scalzo K, Canterford L, Wake M. Sleep duration and body mass index in 0-7-year olds. Arch Dis Child 2011; 96:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/110\">",
"      Lesser DJ, Bhatia R, Tran WH, et al. Sleep fragmentation and intermittent hypoxemia are associated with decreased insulin sensitivity in obese adolescent Latino males. Pediatr Res 2012; 72:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/111\">",
"      Koren D, Levitt Katz LE, Brar PC, et al. Sleep architecture and glucose and insulin homeostasis in obese adolescents. Diabetes Care 2011; 34:2442.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Drug Administration, changes to prescribing information for Zyprexa, released 1/4/2010 file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm198402.htm (Accessed on February 01, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/113\">",
"      Pasarica M, Shin AC, Yu M, et al. Human adenovirus 36 induces adiposity, increases insulin sensitivity, and alters hypothalamic monoamines in rats. Obesity (Silver Spring) 2006; 14:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/114\">",
"      Atkinson RL, Dhurandhar NV, Allison DB, et al. Human adenovirus-36 is associated with increased body weight and paradoxical reduction of serum lipids. Int J Obes (Lond) 2005; 29:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/115\">",
"      Gabbert C, Donohue M, Arnold J, Schwimmer JB. Adenovirus 36 and obesity in children and adolescents. Pediatrics 2010; 126:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/116\">",
"      Angelakis E, Armougom F, Million M, Raoult D. The relationship between gut microbiota and weight gain in humans. Future Microbiol 2012; 7:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/117\">",
"      B&auml;ckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004; 101:15718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/118\">",
"      DiBaise JK, Zhang H, Crowell MD, et al. Gut microbiota and its possible relationship with obesity. Mayo Clin Proc 2008; 83:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/119\">",
"      Kalliom&auml;ki M, Collado MC, Salminen S, Isolauri E. Early differences in fecal microbiota composition in children may predict overweight. Am J Clin Nutr 2008; 87:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/120\">",
"      Cho I, Yamanishi S, Cox L, et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature 2012; 488:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/121\">",
"      Trasande L, Blustein J, Liu M, et al. Infant antibiotic exposures and early-life body mass. Int J Obes (Lond) 2013; 37:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/122\">",
"      Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/123\">",
"      Schecter A, Malik N, Haffner D, et al. Bisphenol A (BPA) in U.S. food. Environ Sci Technol 2010; 44:9425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/124\">",
"      Calafat AM, Ye X, Wong LY, et al. Exposure of the U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003-2004. Environ Health Perspect 2008; 116:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/125\">",
"      Takai Y, Tsutsumi O, Ikezuki Y, et al. Preimplantation exposure to bisphenol A advances postnatal development. Reprod Toxicol 2001; 15:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/126\">",
"      Somm E, Schwitzgebel VM, Toulotte A, et al. Perinatal exposure to bisphenol a alters early adipogenesis in the rat. Environ Health Perspect 2009; 117:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/127\">",
"      Vom Saal FS, Nagel SC, Coe BL, et al. The estrogenic endocrine disrupting chemical bisphenol A (BPA) and obesity. Mol Cell Endocrinol 2012; 354:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/128\">",
"      Carwile JL, Michels KB. Urinary bisphenol A and obesity: NHANES 2003-2006. Environ Res 2011; 111:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/129\">",
"      Lang IA, Galloway TS, Scarlett A, et al. Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. JAMA 2008; 300:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/130\">",
"      Melzer D, Osborne NJ, Henley WE, et al. Urinary bisphenol A concentration and risk of future coronary artery disease in apparently healthy men and women. Circulation 2012; 125:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/131\">",
"      Trasande L, Attina TM, Blustein J. Association between urinary bisphenol A concentration and obesity prevalence in children and adolescents. JAMA 2012; 308:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/132\">",
"      Bouchard C. Genetic determinants of regional fat distribution. Hum Reprod 1997; 12 Suppl 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/133\">",
"      Speiser PW, Rudolf MC, Anhalt H, et al. Childhood obesity. J Clin Endocrinol Metab 2005; 90:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/134\">",
"      Reinehr T, Hinney A, de Sousa G, et al. Definable somatic disorders in overweight children and adolescents. J Pediatr 2007; 150:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/135\">",
"      Vaisse C, Clement K, Durand E, et al. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest 2000; 106:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/136\">",
"      Dubern B, Bisbis S, Talbaoui H, et al. Homozygous null mutation of the melanocortin-4 receptor and severe early-onset obesity. J Pediatr 2007; 150:613.",
"     </a>",
"    </li>",
"    <li>",
"     Leibel RL, Chua SC, Rosenbaum M. Obesity. In: The Metabolic and Molecular Bases of Inherited Disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 2001. p.3965.",
"    </li>",
"    <li>",
"     Pediatric Obesity. In: Pediatric Nutrition Handbook, 6th ed, Kleinman R (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.733.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/139\">",
"      Bougn&egrave;res P, Pantalone L, Linglart A, et al. Endocrine manifestations of the rapid-onset obesity with hypoventilation, hypothalamic, autonomic dysregulation, and neural tumor syndrome in childhood. J Clin Endocrinol Metab 2008; 93:3971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/140\">",
"      Ize-Ludlow D, Gray JA, Sperling MA, et al. Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation presenting in childhood. Pediatrics 2007; 120:e179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/141\">",
"      Mantzoros CS, Rifas-Shiman SL, Williams CJ, et al. Cord blood leptin and adiponectin as predictors of adiposity in children at 3 years of age: a prospective cohort study. Pediatrics 2009; 123:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/142\">",
"      Chiavaroli V, Giannini C, D'Adamo E, et al. Insulin resistance and oxidative stress in children born small and large for gestational age. Pediatrics 2009; 124:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/143\">",
"      Renom Espineira A, Fernandes-Rosa FL, Bueno AC, et al. Postnatal growth and cardiometabolic profile in young adults born large for gestational age. Clin Endocrinol (Oxf) 2011; 75:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/144\">",
"      Efstathiou SP, Skeva II, Zorbala E, et al. Metabolic syndrome in adolescence: can it be predicted from natal and parental profile? The Prediction of Metabolic Syndrome in Adolescence (PREMA) study. Circulation 2012; 125:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/145\">",
"      Huxley R, Owen CG, Whincup PH, et al. Is birth weight a risk factor for ischemic heart disease in later life? Am J Clin Nutr 2007; 85:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/146\">",
"      Barker DJ, Winter PD, Osmond C, et al. Weight in infancy and death from ischaemic heart disease. Lancet 1989; 2:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/147\">",
"      Fernandez-Twinn DS, Ozanne SE. Mechanisms by which poor early growth programs type-2 diabetes, obesity and the metabolic syndrome. Physiol Behav 2006; 88:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/148\">",
"      Plagemann A. Perinatal nutrition and hormone-dependent programming of food intake. Horm Res 2006; 65 Suppl 3:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/149\">",
"      van Abeelen AF, Veenendaal MV, Painter RC, et al. Survival effects of prenatal famine exposure. Am J Clin Nutr 2012; 95:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/150\">",
"      Ludwig DS, Currie J. The association between pregnancy weight gain and birthweight: a within-family comparison. Lancet 2010; 376:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/151\">",
"      Deierlein AL, Siega-Riz AM, Adair LS, Herring AH. Effects of pre-pregnancy body mass index and gestational weight gain on infant anthropometric outcomes. J Pediatr 2011; 158:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/152\">",
"      Lawlor DA, Lichtenstein P, L&aring;ngstr&ouml;m N. Association of maternal diabetes mellitus in pregnancy with offspring adiposity into early adulthood: sibling study in a prospective cohort of 280,866 men from 248,293 families. Circulation 2011; 123:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/153\">",
"      Kral JG, Biron S, Simard S, et al. Large maternal weight loss from obesity surgery prevents transmission of obesity to children who were followed for 2 to 18 years. Pediatrics 2006; 118:e1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/154\">",
"      Taveras EM, Rifas-Shiman SL, Belfort MB, et al. Weight status in the first 6 months of life and obesity at 3 years of age. Pediatrics 2009; 123:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/155\">",
"      Fraser A, Tilling K, Macdonald-Wallis C, et al. Association of maternal weight gain in pregnancy with offspring obesity and metabolic and vascular traits in childhood. Circulation 2010; 121:2557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/156\">",
"      Taveras EM, Rifas-Shiman SL, Sherry B, et al. Crossing growth percentiles in infancy and risk of obesity in childhood. Arch Pediatr Adolesc Med 2011; 165:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/157\">",
"      Leunissen RW, Kerkhof GF, Stijnen T, Hokken-Koelega A. Timing and tempo of first-year rapid growth in relation to cardiovascular and metabolic risk profile in early adulthood. JAMA 2009; 301:2234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/158\">",
"      Monteiro PO, Victora CG. Rapid growth in infancy and childhood and obesity in later life--a systematic review. Obes Rev 2005; 6:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/159\">",
"      Ong KK, Loos RJ. Rapid infancy weight gain and subsequent obesity: systematic reviews and hopeful suggestions. Acta Paediatr 2006; 95:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/160\">",
"      Owen CG, Martin RM, Whincup PH, et al. Effect of infant feeding on the risk of obesity across the life course: a quantitative review of published evidence. Pediatrics 2005; 115:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/161\">",
"      Baird J, Fisher D, Lucas P, et al. Being big or growing fast: systematic review of size and growth in infancy and later obesity. BMJ 2005; 331:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/162\">",
"      Belfort MB, Rifas-Shiman SL, Rich-Edwards J, et al. Size at birth, infant growth, and blood pressure at three years of age. J Pediatr 2007; 151:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/163\">",
"      Shehadeh N, Weitzer-Kish H, Shamir R, et al. Impact of early postnatal weight gain and feeding patterns on body mass index in adolescence. J Pediatr Endocrinol Metab 2008; 21:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/164\">",
"      Gardner DS, Hosking J, Metcalf BS, et al. Contribution of early weight gain to childhood overweight and metabolic health: a longitudinal study (EarlyBird 36). Pediatrics 2009; 123:e67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/165\">",
"      Yeung MY. Postnatal growth, neurodevelopment and altered adiposity after preterm birth--from a clinical nutrition perspective. Acta Paediatr 2006; 95:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/166\">",
"      Lucas A, Morley R, Cole TJ. Randomised trial of early diet in preterm babies and later intelligence quotient. BMJ 1998; 317:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/167\">",
"      Thureen PJ. The neonatologist's dilemma: catch-up growth or beneficial undernutrition in very low birth weight infants-what are optimal growth rates? J Pediatr Gastroenterol Nutr 2007; 45 Suppl 3:S152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/168\">",
"      Kerkhof GF, Willemsen RH, Leunissen RW, et al. Health profile of young adults born preterm: negative effects of rapid weight gain in early life. J Clin Endocrinol Metab 2012; 97:4498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/169\">",
"      Ong KK, Northstone K, Wells JC, et al. Earlier mother's age at menarche predicts rapid infancy growth and childhood obesity. PLoS Med 2007; 4:e132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/5/32858/abstract/170\">",
"      Davey Smith G, Steer C, Leary S, Ness A. Is there an intrauterine influence on obesity? Evidence from parent child associations in the Avon Longitudinal Study of Parents and Children (ALSPAC). Arch Dis Child 2007; 92:876.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5874 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-FDF33D9AD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_5_32858=[""].join("\n");
var outline_f32_5_32858=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14724295\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13797121\">",
"      Trends",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Persistence into adulthood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Environmental factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19815865\">",
"      - Sugar-sweetened beverages",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Television",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Video games",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12509546\">",
"      - Exergames",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Sleep",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13986951\">",
"      - Virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12793569\">",
"      - Gut microbiota",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5397879\">",
"      - Toxins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Endocrine disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Metabolic programming",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Nutrition during gestation and early life",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Other maternal endocrine factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14724295\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5874\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5874|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/23/38257\" title=\"figure 1A\">",
"      CDC BMI for age boys 2 to 20 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/2/40993\" title=\"figure 1B\">",
"      CDC BMI for age girls 2 to 20 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/4/3151\" title=\"figure 2\">",
"      Prevalence of overweight in children_IOTF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/30/11758\" title=\"figure 3\">",
"      US trends in childhood obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/17/43288\" title=\"figure 4\">",
"      Abnormal growth in a child with Cushings disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5874|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/28/459\" title=\"table 1\">",
"      Calculation of BMI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/40/24203\" title=\"table 2\">",
"      Weight categories",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/50/27436\" title=\"table 3\">",
"      Drugs that cause weight gain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/24/23949\" title=\"table 4\">",
"      Genetic syndromes associated with obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/36/36428\" title=\"table 5\">",
"      Single gene causes of obesity in animals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/4/8268\" title=\"table 6\">",
"      Single gene defects associated with obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/60/15307\" title=\"table 7\">",
"      Endocrine disorders associated with childhood obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/0/2061\" title=\"table 8\">",
"      ROHHADNET syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?35/14/36070?source=related_link\" title=\"calculator 1\">",
"      Calculator: Body Mass Index (BMI) percentiles for boys (2 to 20 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?34/60/35782?source=related_link\" title=\"calculator 2\">",
"      Calculator: Body Mass Index (BMI) percentiles for girls (2 to 20 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21865?source=related_link\">",
"      Acquired hypothyroidism in childhood and adolescence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/11/8378?source=related_link\">",
"      Clinical evaluation of the obese child and adolescent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/8/134?source=related_link\">",
"      Clinical features, diagnosis, and treatment of Prader-Willi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/50/37674?source=related_link\">",
"      Comorbidities and complications of obesity in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/5/82?source=related_link\">",
"      Diagnosis of growth hormone deficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39257?source=related_link\">",
"      Epidemiology and clinical manifestations of adenovirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3418?source=related_link\">",
"      Etiology and natural history of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/47/32505?source=related_link\">",
"      Infant benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/38/6760?source=related_link\">",
"      Measurement of body composition in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/14/31976?source=related_link\">",
"      Measurement of growth in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13929?source=related_link\">",
"      Pathogenesis of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/30/23010?source=related_link\">",
"      Patient information: My child is overweight (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44760?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Side effect management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/20/12615?source=related_link\">",
"      Screening for and clinical evaluation of obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/47/16122?source=related_link\">",
"      Surgical management of severe obesity in adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_5_32859="Differential diagnosis of pediatric restless legs syndrome";
var content_f32_5_32859=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of pediatric restless legs syndrome (RLS)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Common conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Positional discomfort",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sore leg muscles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ligament sprain/tendon strain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Positional ischemia (numbness)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bruises",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Growing pains",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nocturnal leg cramps",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Less common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other orthopedic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiculopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myelopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fibromyalgia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Complex regional pain syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug-induced akathisia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sickle cell disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Daniel Picchietti, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_5_32859=[""].join("\n");
var outline_f32_5_32859=null;
var title_f32_5_32860="Vasoactive receptor activity";
var content_f32_5_32860=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Vasoactive medication receptor activity and clinical effects",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       Drug",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"       Receptor activity",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       Predominant clinical effects",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Alpha-1",
"      </td>",
"      <td class=\"subtitle2\">",
"       Beta-1",
"      </td>",
"      <td class=\"subtitle2\">",
"       Beta-2",
"      </td>",
"      <td class=\"subtitle2\">",
"       Dopaminergic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Phenylephrine",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       SVR &uarr; &uarr;, CO  &harr;/&uarr;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Norepinephrine",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       SVR &uarr; &uarr;, CO  &harr;/&uarr;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Epinephrine",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       CO &uarr; &uarr;, SVR &darr; (low dose) SVR/&uarr; (higher dose)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"6\" rowspan=\"1\">",
"       Dopamine (mcg/kg/min)*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       0.5 to 2.",
"      </td>",
"      <td class=\"sublist_other\">",
"       0",
"      </td>",
"      <td class=\"sublist_other\">",
"       +",
"      </td>",
"      <td class=\"sublist_other\">",
"       0",
"      </td>",
"      <td class=\"sublist_other\">",
"       ++",
"      </td>",
"      <td class=\"sublist_other\">",
"       CO",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       5. to 10.",
"      </td>",
"      <td class=\"sublist_other\">",
"       +",
"      </td>",
"      <td class=\"sublist_other\">",
"       ++",
"      </td>",
"      <td class=\"sublist_other\">",
"       0",
"      </td>",
"      <td class=\"sublist_other\">",
"       ++",
"      </td>",
"      <td class=\"sublist_other\">",
"       CO &uarr;, SVR &uarr;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       10. to 20.",
"      </td>",
"      <td class=\"sublist_other\">",
"       ++",
"      </td>",
"      <td class=\"sublist_other\">",
"       ++",
"      </td>",
"      <td class=\"sublist_other\">",
"       0",
"      </td>",
"      <td class=\"sublist_other\">",
"       ++",
"      </td>",
"      <td class=\"sublist_other\">",
"       SVR &uarr; &uarr;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dobutamine",
"      </td>",
"      <td>",
"       0/+",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       CO &uarr;, SVR &darr;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Isoproterenol",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       CO &uarr;, SVR &darr;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     +++: Very strong effect; ++: Moderate effect; +: Weak effect; 0: No effect.",
"     <br>",
"      * Doses between 2. and 5. mcg/kg/min have variable effects.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_5_32860=[""].join("\n");
var outline_f32_5_32860=null;
var title_f32_5_32861="Proposed ATPIII LDL goals";
var content_f32_5_32861=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67460%7EPC%2F54585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67460%7EPC%2F54585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Proposed modifications of ATP III LDL-cholesterol goals and cutpoints for therapeutic lifestyle changes and drug therapy in different risk categories",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Risk category",
"       </td>",
"       <td class=\"subtitle1\">",
"        LDL goal",
"       </td>",
"       <td class=\"subtitle1\">",
"        LDL level at which to initiate therapeutic lifestyle changes",
"       </td>",
"       <td class=\"subtitle1\">",
"        LDL level at which to consider drug therapy*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         High risk:",
"        </strong>",
"        Coronary heart disease (CHD) or CHD risk equivalent (10-year risk &gt;20 percent)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        &lt;100 mg/dL (2.58 mmol/L); optional goal &lt;70 mg/dL (1.82 mmol/L) in very high risk",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        &ge;100 mg/dL (2.58 mmol/L)",
"        <sup>",
"         &loz;",
"        </sup>",
"        &ge;",
"       </td>",
"       <td>",
"        100 mg/dL (2.58 mmol/L)",
"        <sup>",
"         &sect;",
"        </sup>",
"        ; &lt;100 mg/dL (2.58 mmol/L) consider drug options",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Moderately high risk:",
"        </strong>",
"        2 or more risk factors (10-year risk 10 to 20 percent)",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        &lt;130 mg/dL (3.36 mmol/L)",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        &ge;130 mg/dL (3.36 mmol/L)",
"        <sup>",
"         &loz;",
"        </sup>",
"        &ge;",
"       </td>",
"       <td>",
"        &ge;130 mg/dL (3.36 mmol/L); 100 to 129 mg/dL consider drug options",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Moderate risk:",
"        </strong>",
"        2 or more risk factors (10-year risk &lt;10 percent)",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        &lt;130 mg/dL (3.36 mmol/L)",
"       </td>",
"       <td>",
"        &ge;130 mg/dL (3.36 mmol/L)",
"       </td>",
"       <td>",
"        &ge;160 mg/dL (4.13 mmol/L)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Lower risk:",
"        </strong>",
"        0 to 1 risk factor**",
"       </td>",
"       <td>",
"        &lt;160 mg/dL (4.13 mmol/L)",
"       </td>",
"       <td>",
"        &ge;160 mg/dL (4.13 mmol/L)",
"       </td>",
"       <td>",
"        &ge;190 mg/dL (4.91 mmol/L); 160 to 189 mg/dL consider drug options",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * When LDL lowering drug therapy is given, it is advised that the intensity of therapy be sufficient to achieve at least a 30 to 40 percent reduction in LDL levels.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     CHD risk equivalents include noncoronary forms of atherosclerotic disease (peripheral arterial disease, abdominal aortic aneurysm, and carotid artery disease), and diabetes. Ten-year risk defined by modified Framingham risk score.",
"     <br/>",
"     &Delta; Very high risk favors the optional LDL goal of &lt;70 mg/dL (1.82 mmol/L) and, in patients with high triglycerides, non-HDL cholesterol goal of &lt;100 mg/dL.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     &ge; Any individual at high or moderately high risk who has lifestyle-related risk factors (eg, obesity, physical inactivity, hypertriglyceridemia, low HDL-cholesterol [&lt;40 mg/dL (1.04 mmol/L)], or metabolic syndrome is a candidate for therapeutic lifestyle changes to modify these risk factors independent of LDL level.",
"     <br/>",
"     &sect; If baseline LDL is &lt;100 mg/dL (2.58 mmol/L), institution of an LDL lowering drug is an option. This can be combined with a fibrate or nicotinic acid if a high-risk person has hypertriglyceridemia or low HDL (&lt;40 mg/dL (1.04 mmol/L).",
"     <br/>",
"     &yen; Risk factors that modify LDL goals include cigarette smoking; hypertension (BP &ge;140/90 mmHg or on antihypertensive medication)s; low HDL-cholesterol (&lt;40 mg/dL [1.03 mmol/L]); family history of premature CHD (CHD in male first degree relative &lt;55 years or CHD in female first degree relative &lt;65 years); age (men &ge;45 years; women &ge;55 years). HDL-cholesterol &ge;60 mg/dL (1.55 mmol/L) counts as a negative risk factor; its presence removes one risk factor from the total count.",
"     <br/>",
"     &Dagger; Optional LDL goal &lt;100 mg/dL (2.58 mmol/L).",
"     <br/>",
"     &dagger; For moderately high risk persons with LDL of 100 to 129 mg/dL (2.58 to 3.35 mmol/L) at baseline or after lifestyle changes, initiation of an LDL lowering drug to achieve an LDL &lt;100 mg/L is an option.",
"     <br/>",
"     ** Almost all people with 0 to 1 risk factor have a 10-year risk &lt;10 percent; thus, 10-year risk assessment in people with 0 to 1 risk factor is not necessary.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation 2002; 106:3143; with modifications from Grundy SM, Cleeman JI, Merz CN, et al, Circulation 2004; 110:227.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Definition of \"very high risk\" in NCEP guidelines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Established coronary heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        PLUS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Multiple major risk factors (especially diabetes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &nbsp;OR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Severe and poorly controlled risk factors (especially continued smoking)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &nbsp;OR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Multple risk factors of the metabolic syndrome (especially triglycerides &ge;200 plus non-HDL-C &ge;130 plus HDL-C &lt;40)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &nbsp;OR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Acute coronary syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Grundy SM, Cleeman JI, Merz NB, et al. Circulation 2004; 110:227.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_5_32861=[""].join("\n");
var outline_f32_5_32861=null;
var title_f32_5_32862="Maximal reduction in patient radiation exposure";
var content_f32_5_32862=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52470&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52470&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    Maximal reduction in patient radiation exposure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 525px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AC: attenuation correction; HF: heart failure; MI: myocardial infarction; MPI: myocardial perfusion imaging; PET: positron emission tomography; SPECT: single photon emission computed tomography; Tc-99m: technetium-99m; Tl-201: thallium-201.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Cerqueira MD, Allman KC, Ficaro EP, et al. Recommendations for reducing radiation exposure in myocardial perfusion imaging. J Nucl Cardiol 2010; 17:709, with kind permission from Springer Science + Business Media B.V. Copyright &copy; 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_5_32862=[""].join("\n");
var outline_f32_5_32862=null;
var title_f32_5_32863="Early stress fracture fifth metatarsal";
var content_f32_5_32863=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Early stress fracture (Torg type 1) of the fifth metatarsal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 341px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The oblique view of this radiograph shows an early stress fracture (Torg type 1) of the fifth metatarsal diaphysis. Note the narrow fracture line (white arrow) and the thickened cortex adjacent to the fracture on the lateral edge of the bone. It is difficult to determine on an oblique view whether this fracture lies in the typical location of a stress fracture (ie, distal to the intermetatarsal joint) or more proximally, where acute fractures typically occur.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_5_32863=[""].join("\n");
var outline_f32_5_32863=null;
